



PRICE EUR7.4
VALUATION (UPSIDE) EUR10.7 (+45%) • EUR11.1 (+51%)

 VALUATION RANGE
 EPS 23e
 EPS 24e

 ¥ -4%
 ¥ -16%
 ¥ -12%
 ¥ -10%

Growth outlook confirmed

21 MARCH 2023 at 09:14*

Thomas Martin

(+44) 203 430 8435 Thomas Martin@exanebnpparibas.com

Enabling the plastic circular economy

Cabka produces reusable transport packaging (pallets and containers) from recycled plastic, a portion of which it recycles itself. During 2022 its products were made using ~86% recycled material, a sector-leading performance. During a turbulent 2022 management demonstrated their ability to navigate a challenging environment, delivering growth and important new contracts with blue-chip customers across a range of industries. This was achieved despite a flood which severely impacted its US operating base; despite this US sales were up ~30% y-o-y. The outlook for the business remains strong into 2023 driven by favourable demand trends as customers seek to reduce their carbon emissions, costs, and achieve circularity within their logistic chains.

Solid top-line growth in 2022, 2023 guidance in-line with our expectations

Top-line growth of ~23% in 2022 (8% vols, 15% price) was in-line with our forecasts, however, costs were a little ahead of our estimates in a year characterised by volatility, resulting in EBITDA ~14% below our forecasts. Operating cash generation was within EUR1.0m of our forecast. The business is set for continued growth with the 2023 guidance range (high single digit revenue growth and 13-15% EBITDA margins) in-line with our expectations. Stabilising energy prices and an expanded hedging program combined with structural growth in higher profitability business lines should underpin margin expansion through the medium-term.

Valuation range of EUR10.7-11.1/sh

We increase our sales forecasts ~4% for 2023-25 but temper our margin normalisation assumptions given costs running ahead of our forecasts. Our EBITDA forecasts therefore decline ~5% in 2023, are ~flat in 2024 and rise ~5% for 2025. Our valuation range falls marginally to EUR10.7-11.1/sh, from EUR11.1-13.2/sh, reflecting our updated forecasts and a modest increase in cost of capital assumptions.

Price (20 March 2023)				EUR7.4	Performance ⁽¹⁾	1w	1m	3m	12m
Market cap (EURm)				182	Absolute(%)	9	6	7	(19)
Free float (EURm)				87	Rel. Sector(%)	8	9	4	`(2)
EV (EURm)				231	Rel. MSCI Small Cap(%)	10	13	3	(9)
3m avg volume (EURm)				0.0	• • • •				, ,
Refinitiv / Bloomberg		CAB	KA.AS / C.	ABKA NA					
Country			Ne	therlands					
Financials	12/23e	12/24e	12/25e	12/26e	Valuation metrics	12/23e	12/24e	12/25e	12/26e
EPS, Adjusted (EUR)	0.23	0.61	0.82	0.89	P/E (x)	32.5	12.1	9.0	8.2
EPS, Company (EUR)	0.23	0.43	0.82	0.43	Net yield (%)	2.0	2.5	3.3	3.6
EPS - Refinitiv (EUR)	0.23	0.47	0.68	-	FCF yield (%)	(1.8)	4.7	8.4	9.8
Net dividend (EUR)	0.15	0.18	0.25	0.27	EV/Sales (x)	`1.Ó	0.9	0.8	0.7
` '					EV/EBITDA (x)	7.8	5.3	4.1	3.6
Sales (EURm)	225	243	258	275	EV/EBITA (x)	23.3	10.6	7.2	6.4
EBITA, Adj. (ÉURm)	9.9	21.3	30.0	32.1	EV/CE (x)	1.6	1.5	1.4	1.2
Net profit, Adj.(EURm)	5.5	15.0	20.2	22.1	. ,				
ROCE (%)	5.1	10.4	13.9	14.2					
Net Debt/EBITDA, Adj. (x)	1.7	1.0	0.6	0.4	All valuation metrics base	nd an adi	untad fiar	roo	

SPONSORED RESEARCH (Not for Distribution in the US): Exane is receiving compensation from Cabka NV to cover and produce research on the stock.* Date and time (London Time) on which the investment recommendation was finalised. It may differ from the date and time of broad dissemination on the website. See Appendix (on p18) for Analyst Certification, Important Disclosures and Non-US Research Analyst disclosures.

Investment thesis and results overview

Helping to solve the world's plastic waste problems – enabling the plastic circular economy

Recycled plastic accounted for 86% of the feedstock used to produce Cabka's reusable transport packaging (RTP) solutions in 2022, of this 46% was processed in-house and 40% was purchased.

Regulations currently prevent the use of recycled plastic in some use cases (eg. food and pharma), necessitating the requirement for ~14% virgin plastic feedstock in 2022. Management hopes ongoing regulatory reviews will reduce the impact of these restrictions over time.

Globally <20% of plastic waste is currently recycled; this needs to increase substantially to transition to a circular economy. Across Europe plastic recycling rates averaged only 14% with an ambition to increase this to 33% by 2030.

Recycled plastic comprises a large number of waste streams of varying quality with different recycling rates achieved across these various streams. Relatively clean and well-sorted waste plastic (for example PET drinks bottles from well-sorted household recycling schemes) is relatively straightforward to recycle; this is not Cabka's area of focus. Cabka focuses on the more challenging waste streams; this makes an important contribution to global recycling rates which are typically hampered by an inability to recycle more challenging waste streams, and offer lower input costs versus product manufacturers reliant upon high purity recycled plastic waste.

It is simply not the case that any plastic product can be cost effectively manufactured from plastic waste streams which are challenging to recycle. Cabka has achieved these high recycling rates through the development of product families (reusable transport packaging) and manufacturing techniques which are specifically suited to manufacturing from more challenging plastic waste streams.




Figure 1: Cabka's value chain, turning hard to recycle plastic waste into innovative reusable transport packaging solutions

Source: Company

This focus on reusable transport packaging manufactured from recycled plastic offers cost and carbon emissions benefits to customers, ensuring growing demand for Cabka's products. Ensuring the circularity of these recycled plastic products Cabka offers to buyback pallets at the end of their life for recycling and re-use.

Cost and ESG factors continue to drive positive outlook

Cabka's total cost of ownership and life-cycle analysis in a standardised use case indicates both carbon and cost savings per trip from its recycled plastic pallets compared to conventional solutions.

Carbon Footprint per trip*
(Index = 100, kg CO2 eq)

CabCube 3.0

EUR pallet

EUR pallet

EUR pallet

Formula Cost per trip*
(Index = 100, € per unit)

EUR pallet

Formula Cost per trip*

Formula Cost per trip*

(Index = 100, € per unit)

Formula Cost per trip*

Formul

Figure 2: Recycled plastic transport packaging offers cost and carbon savings

Source: Company

Clearly different use cases can result in differing carbon and cost benefits per trip for recycled plastic vs traditional products.

The company's products are seeing adoption across a large range of blue-chip customers operating in a range of industries.

Figure 3: Products attractive across blue-chip companies operating in a range of industries

Selected client base



Source: Company

Some significant contract awards during 2022 include:

- US retailer Target: development of a customised folding large container for their distribution network. The product is designed specifically for their automated system improving efficiency and saving labour costs. First deliveries were made in 3Q 2022.
- Pallet pooler CHEP: development of a customised foldable large container exclusively based on recycled content – a key reason Cabka was chosen. Deliveries are expected to commence in 4Q 2023 with an annualised revenue run-rate of ~EUR9m pa.
- BMW: customised foldable large container replacing metal 'gitterboxes' and servicing the entire supply chain. First deliveries are planned for 2Q 2023.

Recycled plastic transport solutions market growing at ~5-7.5% pa

The global reusable transport packaging market is estimated to be worth ~US\$86bn in 2022 of which plastic has a ~9% share.

Consultants estimate the total RTP market is growing at \sim 5% pa, however, plastic products are expected to take increased market share, with consultants estimating growth rates for plastic pallets at up to \sim 7.5% pa, the fastest growing subsegment of the transport packaging industry.

2023 guidance range in-line with our expectations for the business

2023 guidance for high single digit sales growth with a recovery in the EBITDA margin towards 13-15% was in-line with our prior estimates.

A ~4% price increase was put through effective January 2023, reflecting broader inflationary pressures across the business. We anticipate the reversal in energy prices in particular will feed into lower prices during 2023 as prior price increases are reversed. We therefore anticipate volume growth could be in excess of top-line growth in 2023.

Mid-term guidance for high single digit revenue growth, EBITDA margins above 20%, maintenance and replacement capex ~4% of revenues, NWC ~20% of revenues and a 30-35% payout ratio was retained.

2022 results summary and impact on outlook

Cabka reported its first annual results under IFRS following the listing in March 2022. The reported figures incorporated a number of one-offs and an unanticipated accounting treatment for the IPO, resulting in sizeable non-cash accounting gains and losses.

2022 results were in-line with our forecasts at the top line, however, costs were higher than anticipated in a year characterised by input cost volatility.

Record revenues

Record revenues of EUR208.9m were 1% ahead of our EUR207.5m estimate and registered 23% growth y-o-y, of which 8% was organic growth with 15% driven by pricing/cost pass-through.

EBITDA below forecast; higher than anticipated cost impact during volatile 2022

Operational EBITDA (excluding company defined non-operating items) fell 22% y-o-y to EUR22.5m. The accompanying 10.8% operational EBITDA margin in 2022 is down from 17.0% in 2021, driven by the \sim 43% increase in expenses for materials, energy and purchased services.

2022 EBITDA, on a like-for-like basis, was \sim 14% below our forecast owing to higher than anticipated costs.

The reported cost of raw materials/consumables rose significantly, as a percentage of sales, in H2 2022 to 67.5%, from 58.2% in H1 2022. The reported figures included ~EUR3.3m of incremental costs associated with transferring US manufacturing to third party tollers following the flooding event which incapacitated Cabka's US facility, and EUR3.6m of clean-up costs related to flooding. Excluding these the cost of raw materials rose to 61.1% of reported sales in H2 2022.

The early part of H2 2022 saw significant volatility in energy prices, which Cabka has passed on but with a delay, resulting in a temporary negative impact upon reported margins. Furthermore an updated hedging policy (more on this later) may result in delayed flow-through of falling power prices. We do not believe this is an issue for the business, with visibility preferred over exposure to volatility, and the demonstrated ability to pass through cost inflation clearly beneficial to the business.

Cash generation largely in-line during challenging year

Operating cash-flow generation (post w/c) of EUR0.5m was only marginally below our EUR1.5m forecast, but in the context of the challenges to the business during 2022 this was an encouraging result.

Investments for growth ahead of forecast

Investing cash-flows of ~EUR27m were above our ~EUR20m forecast, however, this included a significant element of investment in capacity expansion.

The table below shows a breakdown by key category; as can be seen ~EUR10.1m, or over 50% of capex not dedicated to repair & maintenance, was allocated to expansion of capacity. In addition, an undisclosed portion of the ECO restructuring cost was allocated to expansion of capacity during transfer of equipment to the new consolidated facility; the expansionary capex total below excludes any contribution from this.

The bulk of the investment in machinery relates to expansion in the US to support growth, with this machinery expected to come into operation during H1 2023. Management noted on the conference call the opportunity to build back capacity in an improved fashion following the flood. Site logistics are being examined and improved, recycling capabilities are being upgraded and older equipment is being replaced with more efficient modern equipment. The flooding event provides the opportunity to rebuild using the existing site layout in a more optimal fashion.

The investment in new moulds relates to new product developments, some of which are undertaken in conjunction with clients as part of the offering of customised solutions. In some instances customers pre-pay a portion of the development costs, investing with Cabka in the development process with Cabka retaining exclusive rights to produce the customised product for the customer.

Figure 4: 2022	capex	by	type
EURm			

	2022
Repl & maint	7.4
% of revs	3.5%
Machines (expansion)	5.6
Moulds (expansion)	4.5
ECO restructuring (incl element of expansion)	3.7
Process & automation	1.6
CNA shares	1.8
Other	2.0
Total	26.6
Total expansion	10.1
Expansion as % of capex excl repl/maint	52.6%

Source: Company, BNP Paribas Exane estimates

Capex guidance for 2023 has not been provided, beyond a reiteration of guidance for replacement and maintenance capex at around 4% of sales (we model 4% equating to ~EUR9m in 2023).

On the conference call management estimated ~10% spare capacity exists within the business today. With expectations of high single digit growth rates for the business over the medium-term, we anticipate additional investments in expansion will be required. We have increased our forecast for capex over and above maintenance levels to ~EUR16m in 2023 (i.e. total capex of ~EUR25m in 2023) to continue to build the business to deliver growth.

Management clearly stated investments will be made to deliver growth in areas where they see customer demand, but this growth potential needs to be clearly visible before investments will be sanctioned. There was a clear commitment not to invest too early on the hope of future growth. This can perhaps be correlated with the ~10% spare capacity in the business following not insubstantial investments in 2023, in the context of high single digit revenue growth expectations.

Net debt a little higher than forecast, principally driven by increased growth investments

Slightly lower than anticipated cash generation combined with higher than anticipated outgoings resulted in net debt (incl leases) of EUR44.6m, ~EUR6m above our ~EUR39m forecast. Investment in growth is the principal driver of this difference.

Distribution in-line with prior guidance, but includes a share component

A capital distribution of EUR0.15/sh was announced, consistent with prior guidance at the time of the listing and indicating confidence in the outlook. Following a challenging year the distribution comprises EUR0.05/sh cash and EUR0.1/sh in shares.

Insurance claims covering response to flood; potential future investment to mitigate risks

Flooding in late July 2022 halted operations at Cabka's US facility in St Louis, after which equipment was salvaged and relocated at third party sites to fulfil customer orders. This resulted in additional tolling and material costs since Cabka's US plastic recycling facilities were unavailable as a consequence.

US operations have recommenced following the flood and 30% growth was delivered in the US business during 2022 – quite an achievement in the context of the challenges. The Target contract was a significant driver of growth from 3Q 2022, with additional deliveries expected under the agreement in 2023.

The US business is expected to be fully operational back at the original site by the end of 2Q 2023.

On the conference call management provided further details regarding the response to the flood event. A leading water management company was engaged shortly after the event to study the causes and formulate actions to mitigate the future risk. This involved 2 workstreams:

- $-\,$ Near-term actions to protect operations prior to the start of the rain season in summer 2023 with an estimated ~5yr life
- Longer-term actions to provide longer-term solutions and protection

The near-term actions have been formulated and are expected to cost ~EUR0.8-1.0m, clearly a sensible investment to reduce the risk of a substantial interruption to operations. This compares to a total cost of the 2022 event, including direct costs (clean-up and impairment of machines) plus indirect costs (additional tolling fees to manufacture products through third party facilities) of EUR6.9m.

The longer-term actions are still being studied and no cost estimates have been provided for future investments in flood protection.

Reduced exposure to power price fluctuations through contracting, including increased renewable energy consumption

We have previously written – in some depth – about the challenges presented by last year's highly volatile power price market. These impacts were successfully passed through to end customers whilst delivering high levels of organic growth, minimising the impacts of this volatility. Extreme volatility is, however, clearly unwelcome from a business planning and execution perspective.

Management has acted to address this by revising hedging policies to ensure a higher level of regional (country-specific) hedging, with the intention of largely fixing price exposure in the near-term. The extent to which prices are fixed declines over time, providing near-term visibility to run the business whilst retaining exposure to market prices over time.

This has been achieved through incorporating increased levels of renewable energy within the business; in Belgium solar power PPAs (power purchase agreements) are expected to account for ~30% of 2023 power demand, improving the environmental footprint of the manufacturing process. Cabka intends to publish its first ESG report in the 2022 annual report (25 April 2023) establishing base ambition levels for the business.

In Germany several options are being negotiated to secure renewable energy under PPAs. In addition, the national power price 'brake', which applies a EUR130/MWh cap on 70% of the prior year's consumption for medium-large industrial consumers, will reduce exposure to extreme price fluctuations.

These measures, alongside efficiency measures to reduce overall consumption and a transparent cost pass-through mechanism should significantly reduce exposure to near-term power price swings.

Key charts summarising forecasts

Growth rates and margins normalising on input cost stabilisation

We forecast a normalisation of growth rates in 2023 following two years of exceptionally high growth. During 2022 in particular this was impacted by zero-margin pass through of significant input cost inflation. It is worth noting that, despite this significant cost inflation, volumes accounted for ~8% of 2022 growth (with pricing accounting for ~15%).

Plastic resin costs are significantly down from peak levels attained in 2Q 2022 and have stabilised around 10% above pre-Ukraine war levels. Power prices remain significantly above pre-Ukraine levels, however, they are also significantly below peak levels reached in August 2022.


Furthermore, Cabka has substantially reduced its exposure to spot power prices through contracting (long-term PPAs), the adoption of price protection mechanisms in certain countries (eg German price cap of EUR130/MWh for 70% of consumption) and hedging.

A reduction in zero-margin cost pass-through should start to benefit margins in 2023.


The expansion of high margin business lines, including customised solutions and ECO products, should also benefit margins. In Europe customised solutions revenues grew 53% in 2022 with additional growth anticipated. Restructuring of the ECO products business during 2022 required a temporary shutdown of production which will not recur in 2023, and resulted in expanded production capacity post restructuring.

Whilst management noted some conservatism incorporated in guidance, there remains uncertainty in the economic outlook, not least around the broader cost of credit, the balance between central bank tightening and stimulus, and energy prices this winter. Reflecting this our 2023 margin forecast is towards the lower end of the range.

Figure 5: Anticipate reduced impact of zero-margin cost pass through, benefitting margin development as volumes continue to ramp-up



EBITDA and margins



Mid-term guidance is for EBITDA margins >20% and we forecast this being reached in 2025.


Top line growth and margin expansion drive a \sim 23% CAGR in operating EBITDA (company definition), or a \sim 36% CAGR in BNPPE adjusted EBITDA over the period 2022-27.

NWC and capex requirements to deliver growth

Tight working capital management in 2022 saw working capital fall to \sim 16% of revenues vs mid-term guidance of \sim 20%. Our forecasts incorporate a return to \sim 19% from 2023.

As noted previously we have increased our capex forecasts to maintain capacity as growth is delivered.

Figure 6: Estimates incorporate a return to more normalised NWC and increased capex vs our prior forecasts



Source: BNP Paribas Exane estimates

Cash generation and returns improving


Improving cash generation should drive debt reductions from 2024, after our forecast normalisation of working capital in 2023. The balance sheet could potentially support M&A activity across the fragmented plastic transport packaging market, including plastic recycling to ensure access to sufficient feedstock as growth is delivered.


Top line growth and margin expansion is expected to drive increasing returns, as illustrated below.

Figure 7: Strengthening balance sheet could support M&A; growth expected to drive improving returns

Net debt/(cash)

Capital employed and ROCE





Valuation range EUR10.7-11.1/sh

We set our valuation range at EUR10.7-11.1/sh offering \sim 45%-50% upside, down from EUR11.1-13.2/sh previously. Our valuation range is bounded by our EBITA multiple and DCF based approaches.

Our DCF valuation decreases from EUR13.2/sh to EUR11.1/sh offering 50% upside vs the current share price. We roll forward our DCF to 2024 and update for movements in risk free rates and equity risk premia.

We present below our DCF valuation for Cabka, which incorporates our explicit forecasts to 2028.

Figure	8:	DCF	va	luation
---------------	----	------------	----	---------

Figure 8: DCF valuation												
		2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
Revenues Growth in sales from goods (%)		243 8%	258 6%	275 7%	292 6%	310 6%	329 6%	349 6%	370 6%	388 5%	404 4%	416 3%
Adjusted EBITDA		43	53	57	62	69	74	79	84	89	92	95
EBITDA margin (%)		17.6%	20.6%	20.5%	21.4%	22.2%	22.5%	22.7%	22.8%	22.8%	22.8%	22.8%
(DD&A, excl right of use assets) (Tax)	(21)	(21) (2)	(23) (8)	(24) (8)	(26) (10)	(27) (12)	(28) (13)	(30) (14)	(31) (15)	(33) (15)	(34) (16)	(36) (16)
Operating CF, pre WC WC Operating CF (add back provisions) Underlying cash flow (Acquisitions/disposals) (Capex) FCF to the firm Discounted FCF		41 (2) 39 1 39 0 (27) 13	45 (4) 42 1 42 0 (28) 15	48 (3) 45 1 46 0 (29) 17	52 (3) 49 0 49 0 (30) 19	57 (3) 54 0 54 0 (33) 21	61 (3) 58 0 58 0 (34) 23 15	66 (4) 62 0 62 0 (36) 25	70 (4) 66 0 66 0 (38) 27 15	73 (4) 69 0 69 0 (39) 30	76 (4) 72 0 72 0 (40) 32 15	79 (4) 74 0 74 0 (40) 34 14
NPV Terminal value DCF value Adjusted (net debt)/cash Modelled equity raise post BS date Lease liabilities Revalued minority interests Assoc & revalued investments Pension obligations Equity Value Basic NOSH NOSH to be issued at TP DCF valuation Up/(down)side to current price	144 202 346 (41) 0 (9) 0 0 296 24.7 1.9 11.1 50%					Cos	t of debt (Targe	of equity post tax) it debt % Tax rate WACC growth	10.7% 4.4% 25.0% 27.5% 9.1% 2.0%			

Source: BNP Paribas Exane estimates

We show below the sensitivity of our DCF valuation to WACC and terminal growth rate assumptions.

Figure 9: Sensitivity of our DCF valuation (EUR/sh) to WACC and terminal growth rate

WACC → Terminal growth ↓	8.1%	8.6%	9.1%	9.5%	9.9%
1.00%	11.4	11.5	11.0	10.3	9.7
1.50%	12.0	11.6	11.0	10.7	10.1
2.00%	12.7	11.5	11.1	10.7	10.5
2.50%	13.5	12.2	11.7	11.2	10.9
3.00%	14.1	13.0	11.7	11.4	11.0

We apply a target multiple to 2024 earnings to derive our multiples-based valuation

We show below our multiples-based valuation which applies a 33:67 weighted waste management and recycling peer-group multiple to our 2024 earnings forecasts. Our analysis incorporates the impact of dilutive securities which would be in the money at our target price.

Figure 10: Multiples based valuation range of EUR10.7-11.4/sh Tgt EBITDA multiple 8.1 Tgt EBITA multiple 14.5 2024 EBITDA 42.8 2024 EBIT EV @ tgt multiple 347.0 EV @ tgt multiple 309.7 Adjusted (net debt)/cash Modelled equity raise post BS date Adjusted (net debt)/cash -35.8 -35.8 0.0 0.0 Modelled equity raise post BS date Lease liabilities -8.7 Lease liabilities -8.7 Revalued minority interests 0.0 Revalued minority interests 0.0 Assoc & revalued investments 0.0 Assoc & revalued investments 0.0 Pension obligations 0.0 Pension obligations 0.0 302.6 267.2 **Equity value** Equity value NOSH incl dilution 24.7 NOSH incl dilution 26.6 Value/sh after dilution (EUR/sh) Value/sh after dilution (EUR/sh) 10.7 Up/(down) side 53% Up/(down) side 45%

Financial statements

Figure 11: Summary of changes to estimates

EURm, unless otherwise noted

		Old		New			Va	Variance (absolute)				Variance (%)		
	2023E	2024E	2025E	2023E	2024E	2025E	2023E	2024E	2025E	2023E	2024E	2025E		
Sales	217.6	232.6 243.0	247.1	225.2 233.2	242.5	257.6 266.6	7.7	9.9	10.5	4% 3%	4% 3%	4% 3%		
Gross income	227.3	243.0	258.1	233.2	251.1	200.0	5.9	8.0	8.5	3%	3%	3%		
Adjusted EBITDA EBITDA margin	31.2 14.4%	42.9 18.5%	50.3 20.4%	29.7 13.2%	42.8 17.6%	53.0 20.6%	(1.5) (1.2%)	(0.1) (0.8%)	2.7 0.2%	(5%) (1.2%)	(0%) (0.8%)	5% 0.2%		
g							(,	(0.0)		(,	(0.0)			
Adjusted EBIT	10.9	23.1	30.4	9.9	21.3	30.0	(1.0)	(1.7)	(0.4)	(9%)	(8%)	(1%)		
EBIT margin	5.0%	9.9%	12.3%	4.4%	8.8%	11.6%	(0.6%)	(1.1%)	(0.7%)	(0.6%)	(1.1%)	(0.7%)		
EPS (Co def'n)	0.26	0.50	0.86	0.23	0.61	0.82	(0.03)	0.11	(0.04)	(12%)	22%	(5%)		
EPS (Exane)	0.26	0.68	0.86	0.23	0.61	0.82	(0.03)	(0.07)	(0.04)	(12%)	(10%)	(5%)		
Op CF (pre w/c)	29.6	34.1	42.5	33.1	39.6	48.7	3.5	5.4	6.2	12%	16%	15%		
Op CF (post w/c)	28.2	32.1	39.1	24.4	37.6	45.2	(3.7)	5.5	6.1	(13.3%)	17.2%	15.6%		
Net cash from inv activities	(19.2)	(20.2)	(21.1)	(25.3)	(26.7)	(27.8)	(6.1)	(6.5)	(6.7)	31.8%	31.9%	31.5%		
Net cash from financing	(10.4)	(11.9)	(18.0)	(3.9)	(10.9)	(17.4)	6.5	0.9	0.6	(62.2%)	(7.9%)	(3.2%)		
Net debt/(cash) - inc. leases	35.7	29.7	18.6	49.3	44.4	33.7	13.6	14.8	15.1	38.1%	49.7%	80.9%		

Source: BNP Paribas Exane estimates

Figure 12: Income statement										
	Unit	2019	2020	2021	2022	2023E	2024E	2025E	2026E	2027E
Revenue from sale of goods	EURm	160.6	134.6	170.0	225.2	242.5	257.6	275.2	292.0	225.2
Growth (period on period)	%	2.3%	-16.2%	26.3%	7.8%	7.7%	6.2%	6.8%	6.1%	7.8%
Growth (y-o-y)	%	2.3%	-16.2%	26.3%	7.8%	7.7%	6.2%	6.8%	6.1%	7.8%
Own work capitalised				3.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory changes				0.7	4.5	4.9	5.2	5.5	5.9	4.5
Other op income		1.9	2.9	2.9	3.4	3.6	3.9	4.1	4.4	3.4
Other op income - % of sales		1.2%	2.2%	1.7%	1.5%	1.5%	1.5%	1.5%	1.5%	1.5%
Gross Income	EURm	162.4	137.5	176.6	233.2	251.1	266.6	284.9	302.2	233.2
Growth - period on period (%)		1.7%	-15.4%	28.4%	2.8%	7.7%	6.2%	6.8%	6.1%	2.8%
COGS	EURm	(78.2)	(63.2)	(89.5)	(119.4)	(123.1)	(124.9)	(136.2)	(144.5)	(119.4)
% of sales		-48.7%	-47.0%	-52.7%	-53.0%	-50.7%	-48.5%	-49.5%	-49.5%	-53.0%
Gross profit	EURm	84.2	74.3	87.1	113.8	128.0	141.7	148.7	157.7	113.8
Gross profit margin on sale of goods	%	52.4%	55.2%	51.2%	50.5%	52.8%	55.0%	54.0%	54.0%	50.5%
Personnel expenses	EURm	(34.4)	(31.1)	(37.0)	(42.6)	(46.4)	(43.9)	(45.5)	(47.0)	(42.6)
IPO listing expenses		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other op expenses	EURm	(25.0)	(24.2)	(25.7)	(41.4)	(43.2)	(44.8)	(46.7)	(48.4)	(41.4)
Rptd EBITDA	EURm	24.8	19.0	24.3	29.7	38.4	53.0	56.5	62.4	29.7
Rptd EBITDA margin	%	15.5%	14.1%	14.3%	13.2%	15.8%	20.6%	20.5%	21.4%	13.2%
Co. adj EBITDA margin (IFRS)	%	16.5%	16.3%	17.0%	13.2%	17.6%	20.6%	20.5%	21.4%	13.2%
DD&A		(17.8)	(18.2)	(19.7)	(19.8)	(21.4)	(23.0)	(24.4)	(25.8)	(19.8)
DD&A - IFRS basis		(19.3)	(20.0)	(19.7)						
EBIT	EURm	7.0	0.7	4.7	9.9	16.9	30.0	32.1	36.6	9.9
EBIT margin	%	4.4%	0.6%	2.7%	4.4%	7.0%	11.6%	11.7%	12.5%	4.4%
Net interest cost	EURm	(3.6)	(2.3)	(2.1)	(2.3)	(2.3)	(2.1)	(1.6)	(1.3)	(2.3)
Net other financial items	EURm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income (loss) before tax	EURm	3.5	(1.6)	2.5	7.6	14.6	27.9	30.5	35.3	7.6
Income tax	EURm	(1.4)	(8.0)	(2.5)	(2.1)	(4.0)	(7.7)	(8.4)	(9.7)	(2.1)
Other taxes		(0.8)	(0.8)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (loss) from continuing operations	EURm	1.3	(3.2)	0.1	5.5	10.6	20.2	22.1	25.6	5.5
Profit (loss) from discontinued operations	EURm									
Net income (loss) for the period	EURm	1.3	(3.2)	0.1	5.5	10.6	20.2	22.1	25.6	5.5
Basic EPS	EUR/sh.				0.2	0.4	8.0	0.9	1.0	0.2
Adjusted EPS	EUR/sh.				0.2	0.6	8.0	0.9	1.0	0.2
Dividend declared per share	EUR/sh.	0.00	0.00	0.00	0.15	0.18	0.25	0.27	0.31	0.15
Payout ratio	%				66%	30%	30%	30%	30%	66%

Source: Company, BNP Paribas Exane estimates

Figure 13: Adjusted income statement - co. definitions Co. adjusted Income Statement 2021 2022 2023E 2024E 2025E 2026E 2027E Co. adj Revenue **EURm** 160.6 134.6 170.0 208.9 225.2 242.5 257.6 275.2 292.0 Co. adj EBITDA
Co. adj EBITDA margin
Co. adj underlying EBITDA (IFRS)
Co. adj EBITDA margin (IFRS) 42.8 **EURm** 20.2 28.9 22.5 29.7 53.0 24.9 56.5 62.4 15.5% 17.0% 13.2% 17.6% 20.6% 10.8% 20.5% 21.4% 15.0% EURm 26.4 21.9 28.9 22.5 29.7 42.8 53.0 56.5 62.4 16.5% 16.3% 17.0% 10.8% 13.2% 17.6% 20.6% 20.5% 21.4% **EURm** Co. adj EBIT 2.0 9.3 4.5 21.3 30.0 32.1 36.6 % EURm 4.4% 1.5% 5.4% 2.2% 4.4% 12.5% Co. adj EBIT margin 8.8% 11.6% 11.7% Co. adj net income ex. NCI Co. adj basic EPS 20.2 1.5 0.1 (2.2)5.5 15.0 22.1 25.6 1.3 3.4 0.2 0.6 0.9 1.0

Source: BNP Paribas Exane estimates

Figure 14: Cash flow statement										
		2019	2020	2021	2022	2023E	2024E	2025E	2026E	2027E
Net income	EURm	1.3	(3.2)	0.1	(34.1)	5.5	10.6	20.2	22.1	25.6
DD&A	EURm	17.8	18.2	19.7	18.0	19.8	21.4	23.0	24.4	25.8
Inc in LT accruals	EURm	1.1	0.4	3.5	0.0	0.0	0.0	0.0	0.0	0.0
Net financial items	EURm	3.1	2.1	1.7	2.4	2.3	2.3	2.1	1.6	1.3
Profit/(loss) on equity investees	EURm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(Gains)/losses on disposals of fixed assets	EURm	(0.0)	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Sales gains / (losses)	EURm				0.0	0.0	0.0	0.0	0.0	0.0
Income tax expense	EURm	1.4	8.0	2.5	0.2	2.1	4.0	7.7	8.4	9.7
Income tax (paid)/refunded	EURm	(1.1)	(2.6)	(3.7)	0.0	0.0	(2.2)	(7.7)	(8.4)	(9.7)
Other	EURm	0.0	0.6	(1.4)	27.0	3.4	3.4	3.4	3.4	3.4
Op CF (pre w/c)	EURm	23.6	16.5	22.5	13.5	33.1	39.6	48.7	51.5	56.1
Changes in working capital	EURm	(2.6)	0.2	(5.1)	(13.0)	(8.7)	(1.9)	(3.5)	(3.1)	(3.1)
Op CF (post w/c)	EURm	21.0	16.8	17.4	0.5	24.4	37.6	45.2	48.4	53.0
Acqn/disposal of subsidiaries, net of cash	EURm	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds from sale of PPE	EURm	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0
Acquisition of PPE	EURm	(13.9)	(12.4)	(19.0)	(26.3)	(25.0)	(26.4)	(27.5)	(28.7)	(29.9)
Investment in intangibles	EURm	(0.6)	(0.1)	(0.3)	(0.4)	(0.4)	(0.4)	(0.4)	(0.4)	(0.4)
Disposal of intangibles	EURm	0.3	4.1	2.4	`0.Ó	0.0	0.0	`0.Ó	0.0	0.Ó
Change in current interest bearing receivables	EURm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash interest received	EURm	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1
Sub-lease income received	EURm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	EURm	0.0	0.0	0.0	(1.9)	0.0	0.0	0.0	0.0	0.0
Net cash from investing activities	EURm	(14.1)	(8.5)	(14.5)	(27.1)	(25.3)	(26.7)	(27.8)	(29.0)	(30.2)
Change in external borrowings	EURm	20.5	(17.1)	1.6	(4.8)	(0.3)	(4.8)	(10.7)	(8.7)	0.0
Acquisition of non-controlling interests	EURm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Transactions in own shares	EURm	0.0	0.0	0.0	45.2	0.0	0.0	0.0	0.0	0.0
Dividends paid to non-controlling interests	EURm	0.0	(0.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Dividends to shareholders	EURm	0.0	`0.Ó	0.0	0.0	(1.2)	(3.7)	(4.5)	(6.1)	(6.6)
Cash interest paid	EURm	(3.1)	(2.1)	(1.7)	(1.8)	(2.4)	(2.4)	(2.1)	(1.7)	(1.4)
Leases paid	EURm	`0.Ó								
Other	EURm	0.0	0.0	0.0	(0.9)	0.0	0.0	0.0	0.0	0.0
Net cash from financing	EURm	17.3	(19.4)	(0.2)	37.7	(3.9)	(10.9)	(17.4)	(16.4)	(8.0)
FX effects	EURm	(0.2)	0.8	(0.9)	0.0	0.0	0.0	0.0	0.0	0.0
Other	EURm	(11.3)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Change in cash	EURm	12.7	(10.3)	1.9	11.1	(4.8)	0.0	0.0	3.0	14.8
Cash at the beginning of the period	EURm	6.8	`19.Ś	9.2	10.0	21.0	16.2	16.2	16.2	19.2
Cash at the end of the period	EURm	19.5	9.2	10.0	21.0	16.2	16.2	16.2	19.2	33.9

Source: Company, BNP Paribas Exane estimates

	2019	2020	2021	2022	2023E	2024E	2025E	2026E	2027E
FURm	73.9	64.3	65.6	78.0	83.2	88 1	92.6	96.9	101.0
									2.1
									0.0
									0.0
									0.0
									0.1
									0.0
									0.0
									0.7
									0.0
EURm	77.7	67.5	76.5	82.8	86.3	89.8	94.7	99.4	103.9
ELIDm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
									50.1
									46.1
	20.1	20.5	21.2						0.0
	2.2	17	6.5						10.4
									0.0
									0.0
									0.0
EURM									0.0
EUD									0.0
									33.9
EURM	72.0	56.6	74.7	104.6	104.0	105.2	111.2	120.3	140.6
EURm	149.7	124.1	151.2	187.4	190.4	195.1	205.9	219.7	244.4
EURm	61.8	50.3	39.6	32.6	32.6	32.6	32.6	32.6	32.6
EURm	17.8	12.2	5.5	5.9	5.9	5.9	5.9	5.9	5.9
EURm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EURm	0.5	0.5	1.7	1.8	1.8	1.8	1.8	1.8	1.8
EURm	2.6	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0
EURm	82.6	63.6	47.0	40.3	40.3	40.3	40.3	40.3	40.3
EURm	0.0	0.0	24.4	24.6	24.2	19.4	8.7	0.0	0.0
EURm	0.0	0.0	2.9	2.7	2.7	2.7	2.7	2.7	2.7
EURm	0.0	0.0	1.0	0.7	0.7	0.7	0.7	0.7	0.7
EURm	0.0	0.5	2.2	5.9	6.7	6.6	6.9	7.4	7.7
EURm	20.8	15.2	30.7	35.2	30.0	29.3	31.4	34.0	36.1
EURm	0.1	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EURm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EURm	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EURm	7.9	8.1	9.4	9.6	9.6	9.6	9.6	9.6	9.6
EURm	28.8	26.7	70.7	78.7	74.0	68.4	60.0	54.4	56.8
EURm	111.5	90.3	117.6	119.0	114.3	108.7	100.3	94.7	97.1
FURm	37.3	33 4	33.6	68 4	76 1	86 4	105.6	125.0	147.3
									0.0
EURm	38.3	33.8	33.6	68.4	76.1	86.4	105.6	1 25.0	147.3
	EURM EURM EURM EURM EURM EURM EURM EURM	EURM 2.1 EURM 0.0 EURM 0.0 EURM 0.0 EURM 1.6 EURM 0.0 EURM 77.7 EURM 0.0 EURM 20.1 EURM 20.1 EURM 0.0 EURM 20.1 EURM 0.0 EURM 10.0 EURM 20.1 EURM 0.0 EURM 10.0 EURM 0.0 EURM 10.0 EURM 10.0 EURM 0.0 EURM 0.0 EURM 0.0 EURM 10.0 E	EURM 73.9 64.3 EURM 2.1 1.1 EURM 0.0 0.0 EURM 0.0 0.0 EURM 0.1 0.1 EURM 0.0 0.0 EURM 1.6 2.0 EURM 0.0 0.0 EURM 77.7 67.5 EURM 0.0 0.0 EURM 20.1 20.5 EURM 20.1 20.5 EURM 20.1 20.5 EURM 0.0 0.0 EURM 77.7 67.5 EURM 10.0 0.0 EURM 2.2 1.7 EURM 0.0 0.0 EURM 0.0 0.0 EURM 77.7 67.5 EURM 2.1 20.5 EURM 20.1 20.5 EURM 20.1 20.5 EURM 10.0 0.0 EURM 0.0 0.0 EURM 0.0 0.0 EURM 0.0 0.0 EURM 19.5 9.2 EURM 149.7 124.1 EURM 61.8 50.3 EURM 17.8 12.2 EURM 0.0 0.0 EURM 0.0 0.0 EURM 0.0 0.0 EURM 2.6 63.6 EURM 0.0 0.0 EURM 0.5 0.5 EURM 2.6 63.6 EURM 0.0 0.0 EURM 0	EURM 73.9 64.3 65.6 EURM 2.1 1.1 0.6 EURM 0.0 0.0 8.3 EURM 0.0 0.0 0.0 EURM 0.1 0.1 0.1 EURM 0.0 0.0 0.0 EURM 19.5 9.2 10.0 EURM 72.0 56.6 74.7 EURM 149.7 124.1 151.2 EURM 149.7 124.1 151.2 EURM 0.0 0.0 0.0 EURM 0.5 0.5 1.7 EURM 2.6 63.6 47.0 EURM 0.0 0.0 2.9 EURM 0.0 0.0 1.0 EURM 0.0 0.0 2.9 EURM 0.0 0.0 0.0 E	EURM 73.9 64.3 65.6 78.0 EURM 2.1 1.1 0.6 0.1 EURM 0.0 0.0 8.3 0.0 EURM 0.0 0.0 1.9 3.9 EURM 0.1 0.1 0.1 0.1 0.1 EURM 0.0 0.0 0.0 0.0 0.0 EURM 19.5 9.2 10.0 21.0 EURM 72.0 56.6 74.7 104.6 EURM 149.7 124.1 151.2 187.4 EURM 2.6 0.6 0.1 0.0 EURM 2.6 0.6 0.1 0.0 EURM 2.6 0.6 0.1 0.0 EURM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 EURM 0.0 0.0 0.0 0.0	EURM 73.9 64.3 65.6 78.0 83.2 EURM 2.1 1.1 0.6 0.1 0.5 EURM 0.0 0.0 8.3 0.0 0.0 EURM 0.0 0.0 1.9 3.9 1.8 EURM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 EURM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 EURM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 EURM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 EURM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	EURM 73.9 64.3 65.6 78.0 83.2 88.1 EURM 2.1 1.1 0.6 0.1 0.5 0.9 EURM 0.0 0.0 0.0 8.3 0.0 0.0 0.0 EURM 0.0 0.0 1.9 3.9 1.8 0.0 EURM 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 EURM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 EURM 1.6 2.0 0.0 0.0 0.0 0.0 0.0 0.0 EURM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 EURM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 EURM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	EURM 73.9 64.3 65.6 78.0 83.2 88.1 92.6 EURM 2.1 1.1 0.6 0.1 0.5 0.9 1.3 EURM 0.0 0.0 8.3 0.0 0.0 0.0 0.0 0.0 EURM 0.0 0.0 1.9 3.9 1.8 0.0 0.0 0.0 EURM 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	EURM 73.9 64.3 65.6 78.0 83.2 88.1 92.6 96.9 EURM 2.1 1.1 0.6 0.1 0.5 0.9 1.3 1.7 EURM 0.0 0.0 8.3 0.0 0.0 0.0 0.0 0.0 0.0 EURM 0.0 0.0 1.9 3.9 1.8 0.0 0.0 0.0 0.0 0.0 EURM 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Source: Company, BNP Paribas Exane estimates

Investment case, valuation and risks

Cabka NV

Investment case

Cabka produces value-adding transport packaging solutions from recycled plastic, contributing to the circular economy whilst also targeting high-growth markets. The business is set for substantial growth driven by increased (recycled) plastic penetration of the transport packaging market, and provision of customised solutions to modern, automated, logistic chains.

Valuation methodology

We use a combination of multiples and DCF to value the business.

Risks

To the upside:

Input costs: pass through of cost inflation is driving top-line growth in the near-term; the impact of this could be greater than we assume.

Growth rates: Cabka targets high single digit growth rates, but has recently delivered well in excess of this with strong volume growth aided by cost pass-through. Growth could surprise to the upside.

Margin expansion: Higher than anticipated growth rates, a stronger performance passing through input costs, and/or better cost management within the business could all drive margins ahead of our expectations. Input costs have begun to fall which should help margins; we could have underestimated this impact. Management targets growth in higher margin areas, for example customised solutions and Eco Products, which could contribute in excess of our forecasts.

Economic growth: The market may overestimate the extent to which economic growth slows, or the impact of any such slowdown on the business.

M&A: M&A is part of the strategy and could offer additional growth to the business.

Regulatory: changes in legislation, particularly with regards to recycling, could impact the business. Cabka's business model is broadly aligned with the general regulatory aims, particularly in Europe, to increase recycling/re-use and eventually transition towards a circular economy.

To the downside:

Input costs: Continued ability to pass on cost inflation and the evolution of those input costs. There is a lag impact on cost pass-through which could impact near-term margins. Recycled plastic waste, energy and labour costs are significant input costs to the business, although the breakdown is not disclosed. Rapidly increasing wood prices - a key input cost for wooden pallets with which recycled plastic pallets compete, have made it easier to pass through significant price increases for recycled plastic pallets. Rising prices for wood and recycled plastic are reversing; if they were to diverge recycled plastic pallets could become less competitive compared to wood pallets.

Execution: Delivery of growth ambitions, both top line and margin expansion.

Economic growth: impact of economic cycles on the outlook for the business. The target markets are forecast to grow in excess of GDP, however, they are still exposed to levels of economic activity.

Competition: the market is fragmented, with a small number of large competitors. Cabka has a leading position in terms of recycled plastic provision, but competitors are moving more towards recycled plastic. Cabka notes competing products in the nestable pallets segment, in particular, are expected to enter the market. The focus on customised solutions embedded in the clients' supply chain logistics, and Eco Products made from waste streams which are challenging to recycle, provide some protection from competitive threats.

M&A: The success of any particular transaction will be driven by the merits of that particular transaction, and its integration into the business. Targeted growth opportunities/synergies may not be delivered.

Safe execution of industrial manufacturing operations: the business has industrial manufacturing and materials handling operations across several sites (two of which are operated by third parties). The continued safe operation of these sites is necessary to ensure uninterrupted supply of products. Flooding caused by heavy rain in summer 2022 has severely impacted the company's US manufacturing facility. Insurance coverage is in place.

Regulatory: changes in legislation, particularly with regards to recycling, could impact the business. Increased competition for waste plastic streams could increase pricing but regulation is also likely to be targeted to increase overall recycling rates. Cabka's strategy is to target waste streams which are more challenging to recycle and are, therefore, typically lower cost.

Key shareholders: The company's founder Gat Ramon retains a 46% interest in the business and a seat on the Supervisory Board, consequently he will be able to exert substantial influence over the business. He could vote his shares in a way in which other shareholders do not agree.

Dilution from dilutive instruments: The capital structure incorporates a number of potentially dilutive instruments which could dilute existing shareholders as share price rise. If all of these instruments were to vest, which would require the share price to increase to EUR20/sh, the share count would increase by \sim 25% (6.098m shares) to \sim 30.5m shares. We incorporate the impact of these instruments into our forecasts.

DISCLOSURE APPENDIX

Analyst Certification

I, Thomas Martin, (authors of or contributors to the report) hereby certify that all of the views expressed in this report accurately reflect my personal view(s) about the company or companies and securities discussed in this report. No part of my compensation was, is, or will be, directly, or indirectly, related to the specific recommendations or views expressed in this research report.

Non-US Research Analyst Disclosure

The research analysts at Exane SA (including its branches in the United Kingdom, the European Economic Area or Switzerland) named below were involved in preparing this research report. They are not associated persons of BNP Paribas Securities Corp. and thus they are not registered or qualified in the U.S. as research analysts with the Financial Industry Regulatory Authority (FINRA) or the New York Stock Exchange (NYSE). These non-U.S. analysts are not subject to FINRA Rule 2241 concerning communications with a subject company, public appearances and trading securities held by a research analyst account.

Thomas Martin Exane SA London

branch

BNP Paribas SA and Exane SA Affiliates Involved in Preparation of the Research Report

Exane SA is authorised by the Autorité de contrôle prudentiel et de résolution ("ACPR") and regulated by the Autorité des Marchés Financiers ("AMF") in France.

Exane SA branches based in the European Economic Area are authorized by the ACPR and regulated by the local relevant regulator.

Exane SA Geneva Branch is authorized and regulated by the Swiss Financial Market Supervisory Authority ("FINMA")

Exane SA, London Branch is deemed authorised and regulated by the Financial Conduct Authority. Details of the Financial Services Contracts Regime, which allows EEA-based firms to operate in the UK for a limited period to carry on activities which are necessary for the performance of pre-existing contracts, are available on the Financial Conduct Authority's website.

BNP Paribas Securities Corp. is regulated by FINRA (CRD# 15794) and the Securities and Exchange Commission in the United States.

Research Analyst Compensation

The research analyst(s) responsible for the preparation of this report receive(s) compensation based upon various factors including overall firm revenues, which may include investment banking activities and/or sales and trading activities.

Sponsored Research

The subject Company of this Research report has commissioned Exane to cover its stock and, consequently, Exane has received compensation from the Company for the preparation and dissemination of this research report.

Research Analyst-Specific Disclosures

The research analyst(s) responsible for the preparation of this report (or members of their household) may have a relationship with the companies covered by this research report, as described in the numbered disclosures below. The table immediately below indicates which, if any, of these disclosures apply to the research analyst(s) responsible for preparation of this research report.

Research Analyst(s)	Companies	Disclosures
NONE		

- 1 The research analyst(s) responsible for the preparation of this report or a member of his/her household has/have a financial interest in the securities of the subject company/ies, as indicated in the previous table.
- 2 The research analyst(s) responsible for the preparation of this report or a member of his/her household serve(s) as an officer, director or advisory board member of the subject company/ies indicated in the previous table.
- 3 The research analyst(s) responsible for the preparation of this report received compensation from the subject company/ies indicated in the previous table in the past twelve months.

Exane-Specific Regulatory Disclosures

Exane SA (including Exane SA branches, based in the United Kingdom, in the European Economic Area and in Switzerland), (collectively, "Exane") has relationships with many companies. The numbered disclosures below identify relationships that Exane has with the company(ies) that are the subject of this research report and that must be disclosed under applicable rules.

Companies	Disclosures
Cabka NV	6; 12; 13

- 1 Exane beneficially owns 1% or more of a class of common equity securities of the subject company/ies.
- 2 Exane managed or co-managed an offering of securities for the subject company/ies in the past 12 months.
- 3 Exane received compensation for investment banking services from the subject company/ies in the past 12 months.
- 4 Exane expects to receive or intends to seek compensation for investment banking services from the subject company/ies in the next 3 months.
- 5 Exane is a market maker and/or liquidity provider in the securities of the subject company/ies.
- 6 Exane, received compensation for products and services other than investment banking services from the subject company/ies in the past 12 months.
- 7 Exane had an investment banking, client relationship with the subject company/ies in the last 12 months.
- 8 Exane had a non-investment banking securities services, client relationship with the subject company/ies in the last 12 months.
- 9 Exane had a non-securities services, client relationship with the subject company/ies in the last 12 months.
- 10 Exane beneficially owns at least 0.5% long or short position of the subject company/ies.
- 11 Exane received compensation from a Private Equity firm to carry out a bespoke work related to the subject company/ies in the past 12 months.
- 12 Exane received or expects to receive compensation for non-investment banking services from the subject company/ies in the past 12 months or in the next 3 months
- 13 Sections of this report, with the research summary, target price and rating removed, have been presented to the subject company/ies prior to its distribution, for the sole purpose of verifying the accuracy of factual statements.
- 14 Following the presentation of sections of this report to this subject company, some conclusions were amended.
- 15 A member for Exane senior management is a member of the Board of the issuer.

BNP Paribas-related disclosures

BNP Paribas SA (including BNP Paribas SA branches and affiliates and BNP Paribas Securities Corp.), (collectively, "BNPP") has relationships with many companies. The numbered disclosures below identify relationships that BNPP has with the company(ies) that are the subject of this research report and that must be disclosed under applicable rules.


-	•	
Companies	Disclosures	
- Companio	2 1001000100	
NONE		

- 1 BNPP beneficially owns 1% or more of a class of common equity securities of the subject company/ies.
- 2 BNPP managed or co-managed an offering of securities for the subject company/ies in the past 12 months.
- 3 BNPP received compensation for investment banking services from the subject company/ies in the past 12 months.
- 4 BNPP expects to receive or intends to seek compensation for investment banking services from the subject company/ies in the next 3 months.
- 5 BNPP is a market maker and/or liquidity provider in the securities of the subject company/ies. BNPP is willing to sell to and/or buy from clients, the common equity of the subject company/ies on a principal basis.
- 6 BNPP, received compensation for products and services other than investment banking services from the subject company/ies in the past 12 months.
- 7 BNP Paribas Securities Corp. had an investment banking, client relationship with the subject company/ies in the last 12 months.
- 8 BNP Paribas Securities Corp. had a non-investment banking securities services, client relationship with the subject company/ies in the last 12 months.
- 9 BNP Paribas Securities Corp. had a non-securities services, client relationship with the subject company/ies in the last 12 months.
- 10 BNPP beneficially owns at least 0.5% long or short position of the subject company/ies.
- 11 BNPP received compensation from a Private Equity firm to carry out a bespoke work related to the subject company/ies in the past 12 months.
- 12 Sections of this report, with the research summary, target price and rating removed, have been presented to the subject company/ies prior to its distribution, for the sole purpose of verifying the accuracy of factual statements.
- 13 Following the presentation of sections of this report to this subject company, some conclusions were amended.
- 14 A member for BNPP senior management is a member of the Board of the issuer.

Price and Ratings Chart

Cabka NV

Historical closing price & target price (as of 20/03/2023)



Source: BNP Paribas Exane

Historical rating & target price changes

The latest company-specific disclosures, valuation methodologies and investment case risks for all other companies covered by this document are available on http://cube.exane.com/compliance.

LONDON

Branch of Exane SA 10 Harewood Avenue London NW1 6AA

Tel: (+44) 207 039 9400 Fax: (+44) 207 039 9440

MILAN

Branch of Exane SA Diamante Tower Piazza Lina Bo Bardi 3 20124 Milan

Tel: (+39) 02 89 63 17 13 Fax: (+39) 02 89 63 17 01

NEW YORK

BNP Paribas Securities Corp. 787 Seventh Avenue New York, NY 10017 USA

Tel: (+1) 212 841 2000

PARIS

Exane SA 6 Rue Ménars 75002 Paris France

STOCKHOLM

Sweden

Branch of Exane SA Hovslagargatan 3

111 48 Stockholm

Tel: (+46) 8 5663 9820

Fax: (+46) 8 5063 9751

Tel: (+33) 1 44 95 40 00 Fax: (+33) 1 44 95 40 01

FRANKFURT

Branch of Exane SA Senckenberganlage 19 60325 Frankfurt Germany

Tel: (+49) 69 42 72 97 300 Fax: (+49) 69 42 72 97 301 MADRID

Branch of Exane SA Calle Emilio Vargas, 4 28043 Madrid Spain

. Tel: (+34) 91 114 83 00 Fax: (+34) 91 114 83 01

SAN FRANCISCO BNP Paribas Securities Corp. 201 Mission Street San Francisco, CA 94105 USA Tel: (+1) 212 634 4975

All Exane research documents are available to all clients simultaneously on the Exane website (http://cube.exane.com). Most published research is also available via third-party aggregators such as Bloomberg, Refinitiv, Factset and Capital IQ. Exane is not responsible for the redistribution of research by third-party aggregators.

Important notice: Please refer to our complete disclosure notice and conflict of interest policy available on http://cube.exane.com/compliance

This research is produced by one or more of EXANE SA (including Exane SA branches, based in the United Kingdom, in the European Economic Area and in Switzerland) and BNP Paribas Securities Corp. EXANE SA is authorized by the Autorité de Contrôle Prudentiel et de Résolution ("ACPR") and regulated by the Autorité des Marchés Financiers ("AMF"). Exane SA branches based in the European Economic Area are authorized by the ACPR and regulated by the local relevant regulator. Exane SA Geneva Branch is authorized and regulated by the Swiss Financial Market Supervisory Authority ("FINMA"). Exane SA, London Branch is deemed authorised and regulated by the Financial Conduct Authority. Details of the Financial Services Contracts Regime, which allows EEA-based firms to operate in the UK for a limited period to carry on activities which are necessary for the performance of pre-existing contracts, are available on the Financial

BNP Paribas Securities Corp. is registered and regulated by the Financial Industry Regulatory Authority ("FINRA") and the U.S. Securities and Exchange Commission. In accordance with the requirements of Financial Conduct Authority COBS 12.2.3R and associated guidance, of article 313-20 of the AMF Règlement Général, and of FINRA Rule 2241, Exane's policy for managing conflicts of interest in relation to investment research is published on Exane's web site (cube.exane.com). Exane also follows the guidelines described in the code of conduct of the Association Francise described "Interest transfer and the follows the guidelines described in the code of conduct of the Association Francise described "Interest transfer and the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of the Association Francise described in the Code of Conduct of Code of Conduct of Code of Conduct of Code of Conduct of Code of C managing conflicts of interest in the field of investment research. This code of conduct is available on Exane's web site (http://cube.exane.com).

This research is solely for the private information of the recipients. All information contained in this research report has been compiled from sources believed to be reliable. However, no representation or warranty, express or implied, is made with respect to the completeness or accuracy of its contents, and it is not to be relied upon as such. Opinions contained in this research report represent BNPP's and/or Exane's current opinions on the date of the report only. BNPP and/or Exane are not soliciting an action based upon it, and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy.

While BNPP and/or Exane endeavour to update its research reports from time to time, there may be legal and/or other reasons why BNPP and/or Exane cannot do so and, accordingly, BNPP and/or Exane disclaim any obligation to do so.

This report is provided solely for the information of professional investors who are expected to make their own investment decisions without undue reliance on this report and BNPP and/or Exane accept no liability whatsoever for any direct or consequential loss arising from any use of this report or its contents.

(i) this research is intended for general circulation; (ii) this research does not take into account the specific investment objectives, financial situation or particular needs of any particular person; and (iii) advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the research, before the person makes a commitment to purchase the investment product.

This report may not be reproduced, distributed or published by any recipient for any purpose. Any United States person wishing to obtain further information or to effect a transaction in any security discussed in this report should do so only through BNP Paribas Securities Corp., which has distributed this report in the United States and, subject to the above, accepts responsibility for its contents.

For Institutional and Accredited Investors in Singapore who receive this report, please contact BNP Paribas, acting through its Singapore Branch (company registration number: S71FC2142G; address: 10 Collyer Quay, 34/F Ocean Financial Centre, Singapore 049315; tel: (65) 6210 1288; fax: (65) 6210 1980) for all matters and queries relating to this report.

BNPP has acquired VERNER INVESTISSEMENTS, the parent company of Exane. VERNER INVESTISSEMENTS is wholly owned and controlled by BNPP, which holds 100% of the share capital and voting rights of VERNER INVESTISSEMENTS.


Company description

The business is integrated from plastic recycling through to the manufacture of transport packaging solutions. The company contributes to the circular economy, deliberately targeting plastic waste streams which are challenging to recycle, minimising input costs and increasing overall recycling rates across society. ESG is at the heart of the company's business. Plastic packaging solutions comprise a small fraction of the market today, but are growing at above market rates - they have attractive characteristics for hi-tech logistic chains. Customised solutions offer high margins and offer high retention, being integrated into supply chains.

Management

Tim Litjens, CEO Necip Kupcu, CFO

Ownership structure	
RAM.ON Holdings	46.6%
DSC Executive Holding BV	5.7%
Eikenbosch Holding BV	4.3%
Other employees	1.7%
Other Shareholders	41.7%



Sector calendar

28	Mar.	23	Holmen	B: AGI

31 Mar. 23 Ence: AGM

19 Apr. 23 Verallia: Q1 Results 2023 (18:00 CET)

25 Apr. 23 Cabka NV: Q1 Results 2023

Ence: Q1 Results 2023

Verallia: AGM

Stora Enso: STERV FH - Results 2023 Q1 (08:30 CET) UPM-Kymmene: UPM FH - Results 2023 Q1 (09:30 CET)

26 Apr. 23 Billerud: Q1 Results 2023 (07:00 CET)

27 Apr. 23 Vidrala: Q1 Results 2023 (10:00 CET)

Vidrala: AGM (12:00 CET)

SCA: SCAB SS - Results 2023 Q1 (20:30 CET) Aptargroup Inc: Q1 Earnings 2023 (22:00 CET)

Avery Dennison: AGM (22:30 CET)

28 Apr. 23 Holmen B: Q1 Results 2023 (07:30 CET)

Smurfit Kappa: SKG ID -

Trading Statement 2023 Q1 (08:00 CET) Smurfit Kappa: AGM (11:00 CET)

Aptargroup Inc: AGM (16:00 CET) 03 May 23

04 May 23 Mondi Plc: MNDI LN - Trading update 2023 Q1 (08:00 CET)

24 May 23 Billerud: AGM

08 Jun. 23 Cabka NV: AGM

22 Jun. 23 DS Smith: SMDS LN - Preliminary Results 22/23 FY (08:00 CET)

21 Jul. 23 SCA: SCAB SS - Results 2023 Q2 (01:00 CET)

Stora Enso: STERV FH - Results 2023 Q2 (01:00 CET)

25 Jul. 23 UPM-Kymmene: UPM FH - Results 2023 Q2 (09:30 CET)

02 Aug. 23 Smurfit Kappa: SKG ID - Results 2023 H1 (01:00 CET)

03 Aug. 23 Mondi Plc: MNDI LN -Results 2023 H1 (01:00 CET)

05 Sep. 23 DS Smith: SMDS LN - Trading Statement Q1 23/24 (01:00 CET)

19 Oct. 23 Mondi Plc: MNDI LN - Trading Update 2023 Q3 (01:00 CET) 24 Oct. 23

Stora Enso: STERV FH - Results 2023 Q3 (01:00 CET)


UPM-Kymmene: UPM FH - Results 2023 Q3 (09:30 CET) 27 Oct. 23 SCA: SCAB SS - Results 2023 Q3 (01:00 CET)

01 Nov. 23 Smurfit Kappa: SKG ID -

Trading Statement 2023 Q3 (01:00 CET)

07 Dec. 23 DS Smith: SMDS LN - Preliminary Results 23/24 H1 (01:00 CET)

Product line



Analyst

Thomas Martin (+44) 203 430 8435 Thomas.Martin@exanebnpparibas.com

LONDON (+44) 207 039 9400

PARIS (+33) 1 44 95 40 00

FRANKFURT (+49) 69 42 72 97 300 **MADRID** (+34) 91 114 83 00

MILAN (+39) 02 89 63 17 13 **STOCKHOLM** (+46) 8 5663 9820

NEW YORK (+1) 212 841 2000 **SAN FRANCISCO** (+1) 212 634 4975

Price at 20 Mar. 23: EUR7.4 Valuation range (EUR): 10.7 (+45%) | 11.1 (+51%)

CABKA NV

Marie of manufact bloody models (miles) 1965	Valuation range (EUR): 10.7 (+45%)		202 420 8425							Daner	& Dackad	ing Neth	erlande
Part			203 430 8435							Гареі	o rackay	ing - Neu	enanus
Part		16.0					1						
Second		12.0				-4	4						
Manufact Manufact	3m average volume 0.0					1	morning	h 1					
Mathematical Part		8.0					Why. an	TM					
The part							A A		, m. /				
Company								ALMA A	ы				
Programmer Pro									Mn				
Page	EPS restated NC 46%	3.5						/					
Part				—— Pri	ce	10.7		7.9				7.4	7.4
March Marc			Dec. 17	De c. 18	Dec. 19								Dec. 27e
Personal part													24.693
## Company submitted 1.5													
March Marc	EPS company definition							(1.44)	0.23	0.43	0.82	0.43	0.47
Content													
													5.3
P. P. P. P. P. P. P. P.													0.31
Programme			Dec. 17	De c. 18	Dec. 19	Dec. 20	De c. 21						
Priving	P / E relative to MSCI Small Cap							NC	256%	110%	90%		
Piny													3.3x
Marging 1998													11.8% 1.39x
						0.0%	0.0%	1.9%					4.2%
Principate BIRTIAN 1.5 1													30.0% 0.65x
PATE	EV / Restated EBITDA							16.0x	7.8x	5.3x	4.1x	3.6x	3.0x
Propriess Prop													5.2x
													7.1x 5.8x
Manusam Manu	EV / Capital employed (incl. gross goodwill)							1.7x	1.6x	1.5x	1.4x	1.2x	1.1x
Age Color Material and material mat													189
Personal profession	+ Adjusted net debt		54	62	60				49	44	34	22	7
Personal protest Personal pr								0	0	0	0	0	0
Per Per								0	0	0	0	0	0
Part	P & L HIGHLIGHTS (EURm)												De c. 27e
September 14													292
Pastence (persipte)													(26)
No. Part P	Restated EBITA (b)		4	4	7	2	6	(3)	10	21	30	32	37
Char													
Team			(2)	(2)	(4)	(2)	(2)	(1)	(2)	(2)	(2)	(2)	(1)
Monetime (i)													
Neather Label profit regarder ((10) 0
Part								(34)				22	26
Betton Augustant (b)													26 Dec 27e
Change in WGR													62
Campon INCR	EBITDA (reported)			24						38	53		
Depart Compose	EBITDA adjustment (b)		18 0	(5)	0				0	4	0		0
Post Patricum Fue cash flow (OpPCF)	EBITDA adjustment (b) Other items		18 0 (1)	(5) 2	0 (0)	(1)	1	0	0 3	4 (1)	0 3	3	3
Net mancial interns stangial	EBITDA adjustment (b) Other items Change in WCR		18 0 (1) (1) (1) 15	(5) 2 (1) 20	0 (0) (3) 22	(1) 0 19	1 (5) 21	0 (13) 1	0 3 (9) 24	4 (1) (2) 40	0 3 (4) 53	3 (3) 57	3 (3) 63
Process From Performance 10	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex		18 0 (1) (1) 15 (15)	(5) 2 (1) 20 (26)	0 (0) (3) 22 (14)	(1) 0 19 (13)	1 (5) 21 (19)	0 (13) 1 (27)	0 3 (9) 24 (25)	4 (1) (2) 40 (27)	0 3 (4) 53 (28)	3 (3) 57 (29)	3 (3) 63 (30)
Capital Increase (decrease) Capi	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF)		18 0 (1) (1) 15 (15) 0	(5) 2 (1) 20 (26) (7)	0 (0) (3) 22 (14) 8	(1) 0 19 (13) 7	1 (5) 21 (19) 2	0 (13) 1 (27) (26)	0 3 (9) 24 (25) (1)	4 (1) (2) 40 (27) 13	0 3 (4) 53 (28) 25	3 (3) 57 (29) 28	3 (3) 63 (30) 32
Capital nicrease (decrease) 0	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow		18 0 (1) (1) 15 (15) 0 (0)	(5) 2 (1) 20 (26) (7) (3) (9)	0 (0) (3) 22 (14) 8 (4) 3	(1) 0 19 (13) 7 (5)	1 (5) 21 (19) 2 (5) (4)	0 (13) 1 (27) (26) (3) (29)	0 3 (9) 24 (25) (1) (2) (3)	4 (1) (2) 40 (27) 13 (5) 9	0 3 (4) 53 (28) 25 (10) 15	3 (3) 57 (29) 28 (10) 18	3 (3) 63 (30) 32 (11) 21
Decision Propertic Prope	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions		18 0 (1) (1) 15 (15) 0 (0) 0	(5) 2 (1) 20 (26) (7) (3) (9)	0 (0) (3) 22 (14) 8 (4) 3 0	(1) 0 19 (13) 7 (5) 2	1 (5) 21 (19) 2 (5) (4) 2	0 (13) 1 (27) (26) (3) (29)	0 3 (9) 24 (25) (1) (2) (3)	4 (1) (2) 40 (27) 13 (5) 9	0 3 (4) 53 (28) 25 (10) 15	3 (3) 57 (29) 28 (10) 18	3 (3) 63 (30) 32 (11) 21
Bala Now, group share 16	EBITDA adjustment (b) Other items Other items Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease)		18 0 (1) (1) 15 (15) 0 (0) 0	(5) 2 (1) 20 (26) (7) (3) (9) 0 1	0 (0) (3) 22 (14) 8 (4) 3 0 (2)	(1) 0 19 (13) 7 (5) 2 0 5	1 (5) 21 (19) 2 (5) (4) 2 (8) 0	0 (13) 1 (27) (26) (3) (29) 2 2 43	0 3 (9) 24 (25) (1) (2) (3) 0 0	4 (1) (2) 40 (27) 13 (5) 9 0 0 0	0 3 (4) 53 (28) 25 (10) 15 0	3 (3) 57 (29) 28 (10) 18 0 0	3 (3) 63 (30) 32 (11) 21 0 0
BALANCE SHEET HIGHLIGHTS (EURm) Dec. 17 Dec. 18 Dec. 29 Dec. 24 Dec. 25 Dec. 26 Dec. 27 Dec. 26 Dec. 27 Dec. 26 Dec. 27 Dec. 26 Dec. 27	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid		18 0 (1) (1) 15 (15) 0 (0) 0 1 1 0	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 0 0	0 (0) (3) 22 (14) 8 (4) 3 0 (2) 0	(1) 0 19 (13) 7 (5) 2 0 5 0 (0)	1 (5) 21 (19) 2 (5) (4) 2 (8) 0	0 (13) 1 (27) (26) (3) (29) 2 2 43	0 3 (9) 24 (25) (1) (2) (3) 0 0	4 (1) (2) 40 (27) 13 (5) 9 0 0 0 (4)	0 3 (4) 53 (28) 25 (10) 15 0 0 0 (5)	3 (3) 57 (29) 28 (10) 18 0 0	3 (3) 63 (30) 32 (11) 21 0 0
Next	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid		18 0 (1) (1) 15 (15) 0 (0) 0 1 0 0 0	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 0 7	0 (0) (3) 22 (14) 8 (4) 3 0 (2) 0 0 (2)	(1) 0 19 (13) 7 (5) 2 0 5 0 (0) (7)	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9	0 (13) 1 (27) (26) (3) (29) 2 2 2 43 0 (18)	0 3 (9) 24 (25) (1) (2) (3) 0 0 0 (1)	4 (1) (2) 40 (27) 13 (5) 9 0 0 0 (4) (5)	0 3 (4) 53 (28) 25 (10) 15 0 0 0 (5)	3 (3) 57 (29) 28 (10) 18 0 0 (6) (12)	3 (3) 63 (30) 32 (11) 21 0 0
Pacta Pact	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCESHEET HIGHLIGHTS (EURm)		18 0 (1) (1) 15 (15) 0 (0) 0 1 1 0 0 (1) 16 Dec. 17	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 0 7 18	0 (0) (3) 22 (14) 8 (4) 3 0 (2) 0 0 (2) 20 Dec. 19	(1) 0 19 (13) 7 (5) 2 0 (0) (7) 14 Dec. 20	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9 14 Dec. 21	0 (13) 1 (27) (26) (3) (29) 2 2 43 0 (18) 11 Dec. 22	0 3 (9) 24 (25) (1) (2) (3) 0 0 0 (1) 4 31	4 (1) (2) 40 (27) 13 (5) 9 0 0 (4) (5) 37 Dec. 24e	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e	3 (3) 57 (29) 28 (10) 18 0 0 (6) (12) 50 De c. 26e	3 (3) 63 (30) 32 (11) 21 0 0 (7) (15) 55
Shareholders' funds, group share 33 36 37 33 34 68 73 80 95 111 13	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANGESHEET HIGHLIGHTS (EURm) Net operating assets		18 0 (1) (1) 15 (15) 0 (0) 0 1 0 0 (1) 18 Doc. 17	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 0 7 18 Dec. 18	0 (0) (3) 22 (14) 8 (4) 3 0 (2) 0 0 (2) 20 Dec. 19	(1) 0 19 (13) 7 (5) 2 0 (0) (7) 14 Dec. 20	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9 14 Dec. 21 66	0 (13) 1 (27) (26) (3) (29) 2 2 43 0 (18) 11 Dec. 22	0 3 (9) 24 (25) (1) (2) (3) 0 0 (1) 4 31 Dec. 23e	4 (1) (2) 40 (27) 13 (5) 9 0 (4) (5) 37 Dec. 24e	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e	3 (3) (57 (29) 28 (10) 18 0 0 (6) (12) 50 De c. 26e 99	3 (3) 63 (30) 32 (11) 21 0 0 (7) (15) 55 Dec. 27e 103
Provisions/ Other liabilities 11	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCESHEET HIGHLIGHTS (EURm) Net operating assets WCR		18 0 (1) (1) 15 (0) 0 (0) 1 1 0 0 0 (1) 16 Dec. 17	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 0 7 18 Dec. 18	0 (0) (3) 22 (14) 8 (4) 3 0 (2) 0 0 (2) 20 Dec. 19	(1) 0 19 (13) 7 (5) 2 0 5 0 (0) (7) 14 Dec. 20 65 29	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9 14 Dec. 21 66 34	0 (13) 1 (27) (26) (3) (29) 2 2 43 0 (18) 11 Dec. 22 78 48	0 3 (9) 24 (25) (1) (2) (3) 0 0 0 (1) 4 31 Dec. 23e 84	4 (1) (2) 40 (27) 13 (5) 9 0 0 (4) (5) 37 De c. 246 89 59	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e 94	3 (3) (57 (29) 28 (10) 18 0 0 (6) (12) 50 De c. 26e 99 66	3 (3) 63 (30) 32 (11) 21 0 0 (7) (15) 55
Net financial debt (cash) 54 62 86 87 90c. 20 90c. 2	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCESHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share		18 0 (1) (1) 15 (15) 0 0 0 1 0 0 (1) 18 Dec. 17 69 30 99 33	(5) 2 (11) 20 (26) (7) (3) (9) 0 1 0 7 18 Doc. 18 79 30 110 36	0 (0) (3) 22 (14) 8 (4) 3 0 (2) 0 (2) 20 20 20 20 20 32 108 37	(1) 0 19 (13) 7 (5) 2 0 0 (0) (7) 14 Dec. 20 95 5 33	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9 14 Dec. 21	0 (13) 1 (27) (26) (3) (29) 2 2 2 43 0 (18) 111 Dec. 22 78 48 127 68	0 3 (9) 24 (25) (1) (2) (3) (0) (0) (1) (1) 4 31 Dec. 230 84 57 141 73	4 (1) (2) 40 (27) 13 (5) 9 0 (4) (5) 37 De c. 246 8 80	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e 94 63 156	3 (3) (3) 57 (29) 28 (10) 18 0 0 (6) (12) 50 Dec. 26e 164 111	3 (3) (63 (30) (32) (11) (21) (0 (0) (7) (15) (15) (15) (15) (15) (15) (15) (15
Sales (% change) NC 12.6% 2.3% (16.2%) 26.3% 22.9% 7.8% 7.7% 6.2% 6.8% 6.1% Cryanic sales growth Restated EBITA (% change) NS (8.6%) 89.7% (72.0%) 184.8% NC NC NC 115.6% 40.5% 7.0% 14.0% Restated attributable net profit (% change) NC NC NC NC NC NC NC N	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCE SHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Monorities		18 0 (1) (1) (1) 15 (15) 0 (0) 0 1 1 0 0 (1) 16 Dec. 17 69 30 99 33	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 1 0 0 7 18 Dec. 18 79 30 110 36 1	0 (0) (3) 22 (14) 8 (4) 3 3 0 (2) 0 0 (2) 20 Dec. 19 76 32 108 37 1	(1) 0 19 (13) 7 (5) 5 0 (0) (7) 14 Dec. 20 65 29 95 33	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34	0 (13) 1 (27) (26) (3) (3) (29) 2 2 43 0 (18) 11 Dec. 22 78 48 48 127 68 0	0 3 3 (9) 24 (25) (11) (2) (2) (3) 0 0 (11) 4 311 Dec. 23e 84 57 141 73 0	4 (1) (2) 40 (27) 133 (5) 9 9 0 0 (4) (5) 37 Coc. 24e 89 59 148 80 0	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e 94 63 156 95	3 (3) (57 (29) 28 (10) 18 0 (6) (12) 50 Doc. 256 99 66 164 111 0	3 (3) (63) (63) (30) (32) (11) (21) (0) (7) (15) (15) (15) (15) (15) (15) (15) (15
Paragenic sales growth Restated EBITA (% change) NS (8.6%) 89.7% (72.0%) 184.8% NC NC NC 115.6% 40.5% 7.0% 14.0% 15.9% Restated EBITA (% change) NC NC NC NC NC NC NC N	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCESHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash)		18 0 (1) (1) (1) (5) (0) (0) (0) (1) (1) 16 Dec. 17 69 30 99 33 1 11 54	(5) 2 (11) 20 (26) (27) (3) (9) (0) 1 0 0 7 18 Dec. 18 79 30 110 366 1 1 111 62	0 (0) (3) 22 (14) 8 (4) 3 0 (2) 0 0 (2) 20 Doc. 19 76 32 108 37 1 1	(1) 0 19 (13) 7 (5) 5 0 (0) (7) 14 Dec. 20 65 29 95 33 3 0 10 10 10 10 10 10 10 10 10	1 (5) 21 (19) 2 (6) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62	0 (13) 1 (27) (26) (3) (29) 2 2 43 0 (18) 11 Dec. 22 48 127 68 0 18 0 18	0 3 3 (9) 24 (25) (11) (2) (3) 0 0 (1) 4 . 31 1 Dec. 230 844 57 141 73 0 0 23 49	4 (1) (2) 40 (27) (5) (5) 9 0 0 (4) (5) 37 7 Dec. 24e 89 59 148 80 0 29 44	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e 94 63 156 95 0	3 (3) (57 (29) (29) (29) (21) (10) (10) (10) (10) (10) (10) (10) (1	3 (3) (3) (63 (30) (32 (11) (21 (10) (10) (10) (10) (10) (10) (10) (10
Restated EITIFA (% change)	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCE SHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Mnortities Provisions/ Other liabilities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%)		18 0 (1) (1) (1) 15 (0) (0) 0 1 0 0 (1) 16 Dec. 17	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 1 0 0 7 18 Dec. 18 79 30 110 36 1 11 62 Dec. 18	0 (0) (3) 22 (14) 8 (4) 3 3 0 0 0 0 (2) 0 0 (2) 20 Dec. 19 76 32 108 37 1 11 60 Dec. 19	(1) 0 19 (13) 7 7 7 (5) 2 0 (0) (7) 14 Dec. 20 65 29 95 33 0 10 53 Dec. 20	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21	0 (13) (17) (26) (27) (28) (29) (29) (29) (29) (43) (09) (18) (19) (19) (19) (19) (19) (19) (19) (19	0 3 3 (9) 24 (25) (11) (2) (3) 0 0 0 (11) 4 31 1 Dec. 23e 84 73 0 23 49 Dec. 23e	4 (1) (2) 40 (27) 133 (5) 9 9 0 0 (4) (5) 37 Dec. 24e 88 80 0 29 44 Dec. 24e	0 3 (4) 53 (28) 25 (10) 15 0 0 0 (5) (11) 47 Dec. 25e 94 63 156 95 0	3 (3) (57 (29) 28 (10) 18 (10) (10) (10) (10) (10) (10) (10) (10)	3 (3) (3) (30) (32) (21) (11) (21) (0) (0) (7) (15) (55) (9) (9) (172) (130) (0) (7) (7) (15) (15) (15) (15) (15) (15) (15) (15
Personnel costs / Sales 22.29	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCE SHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Mnortites Provisions/ Other liabilities Net financial debt (cash) IFNANGIAL RATIOS (%) Sales (% change)		18 0 (1) (1) (1) 15 (0) (0) 0 1 0 0 (1) 16 Dec. 17	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 1 0 0 7 18 Dec. 18 79 30 110 36 1 11 62 Dec. 18	0 (0) (3) 22 (14) 8 (4) 3 3 0 0 0 0 (2) 0 0 (2) 20 Dec. 19 76 32 108 37 1 11 60 Dec. 19	(1) 0 19 (13) 7 7 7 (5) 2 0 (0) (7) 14 Dec. 20 65 29 95 33 0 10 53 Dec. 20	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21	0 (13) (17) (26) (27) (28) (29) (29) (29) (29) (43) (09) (18) (19) (19) (19) (19) (19) (19) (19) (19	0 3 3 (9) 24 (25) (11) (2) (3) 0 0 0 (11) 4 31 1 Dec. 23e 84 73 0 23 49 Dec. 23e	4 (1) (2) 40 (27) 133 (5) 9 9 0 0 (4) (5) 37 Dec. 24e 88 80 0 29 44 Dec. 24e	0 3 (4) 53 (28) 25 (10) 15 0 0 0 (5) (11) 47 Dec. 25e 94 63 156 95 0	3 (3) (57 (29) 28 (10) 18 (10) (10) (10) (10) (10) (10) (10) (10)	3 (3) (3) (63 (30) (32 (11) (21 (10) (10) (10) (10) (10) (10) (10) (10
Restated EBITA margin 13.0% 12.3% 15.5% 15.0% 14.9% 6.3% 13.2% 17.6% 20.6% 20.5% 21.4% Restated EBITA margin 2.9% 2.4% 4.4% 1.5% 3.3% (1.5%) 4.4% 8.8% 17.6% 11.7% 12.5% 12.	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCE SHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Mnorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change)		18 0 (1) (1) (1) 15 (15) 0 (0) 0 1 0 (1) 16 Dec. 17 69 30 99 33 1 1 11 54 Dec. 17 NC	(5) 2 (1) 20 (26) (26) (7) (3) (9) 0 1 1 0 0 7 7 18 Dec. 18 79 30 6 1 1 1 62 Dec. 18 12.6% (8.6%)	0 (0) (3) (22 (14)) 8 (4) (3) 0 (2) (2) (20 Dec. 19 11 11 11 11 11 11 11 11 11 11 11 11	(1) 0 19 (13) 7 (5) 5 0 (0) (7) 14 Dec. 20 10 53 Dec. 20 (16.2%)	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3%	0 (13) (27) (26) (3) (29) (29) (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2	0 0 3 9 24 (25)5 (11) (2) (2) (3) 0 0 0 (1) 4 57 73 0 0 23 49 Dec. 239 7.8%	4 (1) (2) 40 (27) 13 (5) 9 0 0 (4) (5) 15 59 59 59 148 80 0 0 29 44 Dec. 24e 7.7%	0 3 (4) 53 (28) 25 (10) 0 0 (5) (11) 47 Dec. 25e 94 63 156 95 0 32 34 Dec. 25e 6.2%	3 (3) (57 (29) 28 (10) 18 (10) 0 (6) (12) 2 (10) 26 (1	3 (3) (63 (30) (32) (11) (21 (11) (21 (15) (15) (15) (15) (15) (15) (15) (15
Tax rate NC 53,1% of 1.0% 66.1% of 1.0% of 1	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCESHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Restated EBITA (% change) Restated attributable net profit (% change)		18 0 (1) (1) (1) 15 (15) 0 (0) 0 1 0 0 (1) 16 Dec. 17 69 30 99 33 1 11 54 Dec. 17 NC	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 1 0 0 7 18 Dec. 18 79 30 110 36 1 1 11 62 Dec. 18 12.6% NC	0 (0) (3) 22 (14) 8 (4) 3 0 (2) 0 0 (2) 20 Doc. 19 76 76 76 76 89.7%	(1) 0 19 (13) 7 (5) 2 0 (5) 5 0 (0) (7) 14 Dec. 20 65 29 95 10 33 0 10 53 Dec. 20 (16.2%) N/C	1 (5) 21 (19) 2 (6) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3%	0 (13) (27) (26) (3) (29) (2) (2) (2) (2) (2) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4	0 3 3 9) 24 (255) (11) (2) (2) (3) 0 0 (1) 4 31 Dec. 25e 7 141 73 0 233 49 Dec. 25e 7 8%	4 (1) (2) 40 (27) 13 (5) 9 0 (4) (5) 37 Dec. 24e 80 0 29 148 80 0 29 44 Dec. 24e 7.7%	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e 94 63 156 95 0 32 34 Dec. 25e 6.2%	3 (3) (57 (29) (29) (29) (28) (10) (18) (0 (6) (12) (50) (12) (50) (16) (17) (18) (18) (18) (18) (18) (18) (18) (18	3 (3) (3) (32 (11) (21) (2
Net margin 0.0% (1.1%) 0.8% (1.5%) 0.6% (3.4%) 2.4% 6.2% 7.9% 8.0% 8.8% Capax / Sales 10.7% 16.8% 9.0% 9.3% 11.4% 12.8% 11.3% 11.0% 10.8% 10.6% 10.4% 0.6% 7.9% 10.1% 11.1% VCR / Sales 0.3% (4.2%) 4.8% 5.1% 1.0% (1.2.5%) (0.4%) 5.4% 9.7% 9.1% 11.1% VCR / Sales 0.3% 0.8% 0	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) Dividends paid Increase (decrease) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change)		18 0 (1) (1) (1) 15 (15) 0 (0) 0 1 0 0 (1) 16 Dec. 17 69 30 99 33 1 11 54 Dec. 17 NC	(5) 2 (11) 20 (26) (7) (3) (9) (9) (0 (7) (12) (12) (13) (14) (15) (15) (15) (15) (15) (15) (15) (15	0 (0) (3) 22 (14) 8 (4) 3 3 3 0 (2) 0 0 (2) 20 Dec: 19 7 6 6 6 0 0 0 2 10 10 10 10 10 10 10 10 10 10 10 10 10	(1) 0 0 19 (13) (13) (7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	1 (5) 21 (19) 2 (6) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3% 184.8% NC 21.8%	0 (13) (17) (26) (26) (29) (29) (29) (29) (29) (43) (48) (18) (19) (18) (19) (19) (19) (19) (19) (19) (19) (19	0 3 3 (9) 24 (25) (11) (2) (3) (3) (0) (0) (1) (1) 4 4 (21) (23) (23) (23) (23) (23) (23) (23) (23	4 (1) (2) 40 (27) 133 (5) 9 9 0 (4) (5) 37 Dec. 24e 89 59 148 80 0 29 44 4 Dec. 24e 7.7%	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e 94 63 156 95 32 34 Dec. 25e 6.2%	3 (3) 57 (29) 28 88 (10) 18 0 0 (6) (12) 550 Do c. 266 164 111 0 36 22 Do c. 266 6.8% 7.0% 9.1% 16.5%	3 (3) (63 (30) (32) (11) (21 (11) (21 (15) (15) (15) (15) (15) (15) (15) (15
Capex / Sales	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share EALANCESHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Personnel costs / Sales Restated EBITA (% change) Personnel costs / Sales Restated EBITA margin Restated EBITA margin		18 0 (1) (1) (1) 15 (15) 0 (0) 0 1 1 0 0 (1) 1 16 Dec. 17 69 33 1 11 11 NC NS NC 22.2% 13.0% 2.9%	(5) 2 (11) 20 (26) (77) (3) (9) (9) (0 7 7 18	0 (0) (3) (22 (14) 8 (4) 3 0 (2) 0 0 (2) 20 Dec. 19 76 32 108 37 1 11 60 Dec. 19 2.3% NC 221.4% 15.5% NC 221.4%	(1) 0 0 19 (13) 7 (5) 2 0 (0) (0) (7) 144 Dec. 20 65 29 95 33 3 Dec. 20 (16.2%) NC 23.1% 15.0% 1.5%	1 (5) 21 (19) 2 (6) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3% NC 21.8% 14.9% 3.3%	0 (13) (17) (26) (27) (26) (3) (29) (29) (2 (29) (18) (19) (19) (19) (19) (19) (19) (19) (19	0 3 3 (9) 24 (25) (11) (2) (3) (3) (0) (1) (4) (4) (5) (7) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1	4 (1) (2) 40 (27) (5) (5) 9 0 0 (4) (5) 37 7 De G. 24e 89 59 148 80 0 29 44 De C. 24e 7.7% 115.6% 19.1% 17.6% 8.8%	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e 94 63 156 95 0 32 32 34 Dec. 25e 6.2% 40.5% 34.9% 11.6%	3 (3) (57 (29) (29) (29) (21) (10) (10) (10) (10) (10) (10) (10) (1	3 (3) (3) (63 (30) (32 (11) (21 (0) (0) (15) (15) (15) (15) (15) (15) (15) (15
WCR / Sales 21.8% 18.8% 19.7% 21.8% 20.0% 23.2% 25.3% 24.3% 24.3% 23.9% 23.5%	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCESHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Restated EBITA (% change) Restated EBITA margin		18 0 (1) (1) (1) 15 (0) (0) 0 1 0 0 (1) 16 Dec. 17 69 30 99 33 1 11 54 Dec. 17 NC	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 1 0 0 7 7 18 Dec. 18 12.6% (8.6%) NC 12.3% 2.4% 53.1%	0 (0) (3) (22 (14)) 8 (4) 3 0 (2) (2) (20 Dec. 19 11 11 6) Dec. 19 2.3% 89.7% NC 15.5% 4.4% 63.1%	(1) 0 19 (13) 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3% 184.8% NC	0 (13) (17) (26) (27) (28) (29) (29) (29) (29) (29) (18) (19) (19) (19) (19) (19) (19) (19) (19	0 0 3 9 9 9 24 (25)5 (11) (2) (3) 0 0 0 0 (11) 4 1 57 141 1 7 3 1 9 Dec. 230 7.8% NC RC 18.9% 13.2% 4.4% 27.5%	4 (1) (2) 40 (27) 13 (5) 9 0 0 (4) (5) 37 Doc. 24e 89 59 148 80 0 29 44 Doc. 24e 7.7% 175.2% 17.6% 8.8% 27.5%	0 3 (4) 53 (28) 25 (10) 0 0 (5) (11) 47 Doc. 25e 94 63 156 95 0 32 34 Dec. 25e 6.2%	3 (3) (57 (29) 28 (10) 18 (10) 0 (6) (11) 15 (12) 15 (10) 16 (10) 17 (3 (33) (33) (32) (32) (32) (11) (21) (0) (0) (7) (15) (55) (55) (69) (97) (172) (130) (0) (97) (15) (15) (16) (16) (16) (16) (16) (16) (16) (16
Capital employed (excl. gdw./intangibles) / Sales 68.6% 67.9% 66.7% 69.5% 58.6% 60.5% 62.5% 61.0% 60.7% 59.6% 58.8% ROE (0.1%) (5.0%) 3.5% (6.5%) 2.2% (10.4%) 7.6% 18.9% 21.2% 19.8% 19.9% 19.9% 69.8% 66.6% 68.6% 56.9% 35.9% 21.2% 19.8% 19.9% 69.8% 69.6% 68.6% 56.9% 35.9% 20.9% 69.8% 69.6% 35.9% 21.2% 19.8% 19.9% 69.9%	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCESHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Mnortites Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Restated EBITDA margin Restated EBITDA margin Restated EBITA margin Tax rate Net margin		18 0 (1) (1) (1) 15 (15) 0 (0) 0 1 0 0 (1) 16 Dec. 17 69 30 99 33 1 11 54 Dec. 17 NC NS NC 22.2% NC 2.2% NC 0.0%	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 1 0 0 7 18 Dec. 18 79 30 110 36 1 1 11 62 Dec. 18 12.6% (8.6%) NC 21.1% (2.4% 53.1% (1.196)	0 (0) (3) (22 (14) 8 (4) 8 (4) 3 0 (2) 0 (2) 20 Doc. 19 76 76 76 76 76 76 76 76 76 76 76 76 76	(1) (0) (13) (13) (13) (15) (15) (15) (15) (15) (15) (15) (15	1 (5) 21 (19) (19) (2) (6) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3% NC 21.8% NC 21.8% NC 0.6%	0 (13) (27) (26) (29) (29) (2 (29) (2 (29) (2 (29) (2 (29) (2 (29) (2 (29) (29)	0 3 3 9 9 24 (255) (21 25) (22 (25) (27 25) (2	4 (1) (2) 40 (27) 13 (5) 9 0 0 (4) (5) 5 7 0 C. 24e 80 0 0 29 44 Doc. 24e 7.7% 115.6% 176.2% 8.8% 27.5% 8.8% 27.5% 6.2%	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Doc. 25e 6.29 40.5% 34.9% 17.0% 20.6% 11.6% 27.5%	3 (3) (57 (29) (29) (28) (10) (11) (10) (10) (10) (10) (10) (10	3 (3) (3) (63 (30) (32 (11) (21 (0) (0) (15) (15) (15) (15) (15) (15) (15) (15
ROE (0.1%) (5.0%) 3.5% (6.5%) 2.2% (10.4%) 7.6% 18.9% 21.2% 19.8% 19.6% Gearing 161% 168% 157% 158% 186% 65% 66% 66% 66% 35% 20% 66% 66% 66% 166% 35% 20% 66% 66% 166% 166% 166% 166% 166% 166%	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANGE SHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Restated EBITA (% change) Restated EBITA margin Restated EBITA margin Restated EBITA margin Rest ray in the provision of the provisions of the provisio		18 0 (1) (1) (1) 15 (15) 0 (0) 0 1 0 0 (1) 16 Dec. 17 69 30 99 33 1 1 11 54 CC. 17 NC NS NC 22.2% 13.0% 2.9% NC 0.0% 10.7% 0.0%	(5) 2 (1) 20 (26) (7) (3) (9) 0 1 1 0 0 7 18 Dac. 18 79 30 110 26 20 110 11 11 12 20 20 11 12 20 20 11 11 12 20 20 11 11 12 20 20 11 11 12 20 20 11 11 11 11 11 11 11 11 11 11 11 11 11	0 (0) (3) (22 (14)) 8 (4) 3 0 (2) (2) 20 Doc. 19 76 32 108 37 1 1 11 11 12 2.3% NC 21.4% NC 21.4% 0.8% 4.4% 0.8% 4.8%	(1) 0 19 (13) 7 7 (5) 5 1 % (5) 6 1 % (7) 14 Dec. 20 (16.2%) Dec. 20 (16.2%) (72.0%) NC 23.1% NC (75.0% 1.5% NC (1.5%) 9.3% 5.1%	1 (5) 21 (19) 2 (5) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3% 184.8% NC 21.8% 14.9% 3.3% NC 0.6% 11.4%	0 (13) (17) (26) (27) (26) (29) (29) (29) (29) (18) (19) (19) (19) (19) (19) (19) (19) (19	0 3 3 9 9 24 (25) (11) (2) (3) 0 0 0 (1) 4 3 11 Doc. 230 84 57 141 11 73 0 23 84 57 7.8% NC NC 18.9% 13.2% 4.4% 27.5% 2.4% (1.13% (0.4%) (0.4%) (0.4%)	4 (1) (2) 40 (27) 13 (5) 9 0 0 (4) (5) 9 59 148 80 0 0 29 44 44 Dec.24e 7.7% 115.6% 172.2% 1.8% 6.2% 6.2% 5.4%	0 3 (4) 53 (28) 25 (10) 0 0 (5) (11) 47 Dec. 25e 94 63 156 95 0 32 34 Dec. 25e 6.2% 40.5% 34.9% 17.0% 20.6% 11.6% 27.5% 7.9%	3 (3) (57 (29) 28 (10) 18 (10) 0 0 0 (6) (12) 19 (6) 19 (10) 11 11 1 0 36 22 10 10 10 10 10 10 10 10 10 10 10 10 10	3 (33) (33) (32) (32) (11) (21) (15) (55) (56) (76) (77) (15) (77) (15) (77) (15) (77) (15) (77) (15) (77) (15) (15) (15) (15) (15) (15) (15) (15
EBITDA / Financial charges 9.1x 8.7x 7.0x 8.6x 12.0x 16.5x 13.0x 18.6x 25.xx 35.0x 49.3x Adjusted financial clebt / EBITDA 3.0x 3.2x 2.4x 2.6x 2.5x 3.4x 1.7x 1.0x 0.6x 0.4x 0.1x ROCE, excl. gdw /intangibles 3.1% 2.5% 4.9% 1.5% 4.1% (1.8%) 5.1% 10.5x 13.9x 14.2x 15.4x ROCE, incl. gross goodwill 5.8% 6.0% 5.8% 5.7% 6.1% 6.9% 6.9% 6.9% 6.9% 6.9% 6.9% 6.9% 6.9% 6.9% 6.9% 6.9% 6.9% 6.9%	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCESHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Restated EBITA (% change) Restated EBITA margin Tax rate Net margin Capex / Sales OpFCF / Sales WCR / Sales WCR / Sales WCR / Sales WCR / Sales		18 0 (1) (1) (1) (1) 15 (15) 0 (0) 0 1 1 0 0 (1) 1 16 Dec. 17 69 33 1 1 11 17 NC NS NC 22.2% 13.0% 22.2% NC 22.2% 10.7% 0.3% 21.8%	(5) 2 (11) 20 (26) (7) (3) (9) (9) (0 7) 18 Dec. 18 79 30 110 36 11 11 62 Dec. 18 12.6% (8.6%) NC 21.1% (2.3% (5.1%) (1.1%) 15.1% (1.1%) 16.8% (4.2%) 18.8%	0 (0) (3) (22 (14) 8 (4) 3 0 (2) (20 (15) 6	(1) 0 0 19 (13) 7 (5) 2 0 0 (0) (7) 144 Dec. 20 65 29 95 33 3 Dec. 20 (16.2%) NC (23.1% NC (1.5%) 9.3% NC (1.5%) 9.3% 5.1% 21.8%	1 (5) 21 (19) 2 (6) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 101 26.3% 184.8% NC 21.8% 14.9% NC 0.6% 11.4% 1.0% 20.0%	0 (13) (13) (17) (26) (27) (26) (29) (29) (29) (18) (19) (19) (19) (19) (19) (19) (19) (19	0 3 3 (9) 24 (25) (11) (2) (2) (3) (3) (0) (1) (4) (2) (3) (2) (3) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4	4 (1) (2) 40 (27) 13 (5) 9 0 (4) (5) 37 Dec. 24e 89 9 44 Dec. 24e 7.7% 115.6% 17.2% 19.1% 17.6% 8.8% 27.5% 6.2% 6.2% 11.0% 5.4% 24.3%	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e 94 63 156 95 0 32 34 Dec. 25e 6.2% 40.5% 34.9% 17.0% 20.6% 11.6% 27.5% 27.5% 9.7% 9.7% 9.7%	3 (3) (57 (29) (28) (10) (18) (10) (10) (10) (10) (10) (10) (10) (10	3 (3) (3) (32) (32) (11) (21 (0) (0) (7) (15) (55 (69) (17) (17) (17) (17) (17) (17) (17) (17
Adjusted financial debt / EBITDA 3.0x 3.2x 2.4x 2.6x 2.5x 3.4x 1.7x 1.0x 0.6x 0.4x 0.1x ROCE, excl. gdw./intangibles 3.1% 2.5% 4.9% 1.5% 4.1% (1.8%) 5.1% 10.5% 13.9% 14.2% 15.4% ROCE, incl. gross goodwill 3.0% 2.5% 4.7% 1.5% 4.1% (1.8%) 5.1% 10.5% 13.9% 14.2% 15.4% WACC 5.8% 6.0% 5.8% 5.7% 6.1% 6.7% 6.9%	EBITDA adjustment (b) Other items Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANGESHEET HIGHLIGHTS (EURM) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Restated attributable net profit (% change) Personnel costs / Sales Restated EBITA margin Restated EBITA margin Restated EBITA margin Capex / Sales VCR / Sales		18 0 (1) (1) (1) 15 (15) 0 (0) 0 1 1 0 0 (1) 16 Dec. 17 69 30 99 33 1 1 11 54 Dec. 17 NC NS NC 22.2% 13.0% 2.9% NC 0.0% 10.7% 0.3% 2.1.8% 0.0% 68.6% (0.1%)	(5) 2 (11) 20 (26) (7) (3) (9) 0 1 1 0 0 7 18 Dec. 18 79 30 110 36 1 1 11 12 62 Dec. 18 12.6% NC 21.1% (8.6%) NC 21.1% (2.4% 53.1% (1.1%) 16.8% (4.2%) 18.8% 67.9% (5.0%)	0 (0) (3) (22 (14)) 8 (4) 8 (4) 3 (2) (2) (2) (2) (2) (2) (2) (2) (2) (2)	(1) 0 19 (13) 7 (5) 2 0 (7) (7) 14 Dec. 20 66 62 99 95 33 0 10 53 Dec. 20 (16.2%) NC 23.1% 15.0% NC (2.1.5% NC 24.1% 15.0% NC 25.1% 15.0% NC 26.5% 15.5%	1 (5) 21 (19) 2 (2) (6) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3% NC 21.8% NC 21.8% NC 21.8% 14.9% 3.3% NC 20.6% 11.4% 20.0% 20.0%	0 (13) (13) (17) (26) (26) (29) (29) (29) (29) (29) (18) (18) (18) (19) (19) (19) (19) (19) (19) (19) (19	0 3 3 9 9 24 (255) (21 25) (22 25) (23 3) (25 25) (27	4 (1) (2) (2) (4) (2) (7) (7) (7) (7) (8) (9) (9) (9) (9) (10) (10) (10) (10) (10) (10) (10) (10	0 3 (4) 53 (28) 25 (10) 0 0 (5) 115 0 0 (5) (111) 47 Dec. 25e 63 31 56 95 0 32 34 40.5% 34.9% 17.0% 20.6% 11.6% 20.6% 11.6% 27.5% 7.9% 10.8% 9.97% 24.3% 60.7% 24.3%	3 (3) (57 (29) (29) (29) (28) (10) (18 (0) (10) (12) (20) (10) (10) (10) (10) (10) (10) (10) (1	3 (3) (3) (32 (11) (11) (21 (10) (15) (15) (15) (15) (15) (15) (15) (15
ROCE excl. gdw /intangibles 3.1% 2.5% 4.9% 1.5% 4.1% (1.8%) 5.1% 10.5% 13.9% 14.2% 15.4% ROCE incl. gross goodwill 3.0% 2.5% 4.7% 1.5% 4.1% (1.8%) 5.1% 10.4% 13.9% 14.2% 15.4% WACC 5.8% 6.0% 5.8% 5.7% 6.1% 6.9% 6.9% 6.9% 6.9% 6.9% 6.9%	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share EALANCESHEST HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Personnel costs / Sales Restated EBITA margin Tax rate Net margin Capex / Sales OpFCF / Sales WCR / Sales Capital employed (excl. gdw Jintangibles) / Sales ROE Gearing		18 0 (1) (1) (1) (1) 15 (15) 0 (0) 0 1 1 0 0 (1) 16 Dec. 17 69 30 99 33 1 11 54 Dec. 17 NC NS NC 22.2% 13.0% 29% NC 0.0% 10,7% 0.3% 68.6% (0.1%) 161%	(5) 2 (11) 20 (26) (77) (33) (99) (9) (10) (10) (10) (10) (10) (10) (10) (10	0 (0) (3) (22 (14) 8 (4) 3 0 (2) 0 0 (2) 20 Dec. 19 76 6 32 108 37 1 11 160 Dec. 19 2.3% NC 221.4% 15.5% (63.1% 0.8% 9.0% 4.8% 9.0% 4.8% 9.0% 4.8% 9.0% 4.8% 9.0% 4.8% 9.0% 19.7% 19.7%	(1) 0 0 19 (13) 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	1 (5) 21 (19) 2 (6) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3% 184.8% NC 21.8% 1.0% 0.6% 1.1.4% 1.0% 20.0% 58.6% 2.2%	0 (13) (13) (17) (26) (26) (3) (29) (29) (29) (43) (43) (48) (15) (48) (45) (47) (48) (48) (48) (48) (48) (48) (48) (48	0 3 3 (9) 24 (25) (11) (2) (2) (3) (3) (0) (1) (4) (2) (3) (2) (3) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4	4 (1) (2) 40 (27) 13 (5) 9 0 0 (4) (5) 37 7 De G. 24e 89 59 148 80 0 29 44 De C. 24e 7.7% 17.2% 19.1% 17.6% 17.2% 19.1% 17.6% 17.2% 19.1% 17.6% 17.2% 19.1% 17.6% 5.6% 5.4% 5.4% 5.4% 5.4% 5.4% 5.4% 5.4% 5.4	0 3 (4) 53 (28) 25 (10) 15 0 0 (5) (11) 47 Dec. 25e 94 63 156 95 0 32 34 Dec. 25e 6.2% 40.5% 34.9% 20.6% 11.6% 27.5% 9.7% 9.79% 10.8% 9.79% 24.3% 60.7%	3 (3) (57 (29) (29) (29) (29) (20) (10) (10) (10) (10) (10) (10) (10) (1	3 (3) (3) (63 (30) (32 (11) (21) (2
WACC 5.8% 6.0% 5.8% 5.7% 6.1% 6.7% 6.9% 6.9% 6.9% 6.9% 6.9%	EBITDA adjustment (b) Cher items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial irems + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCE SHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Restated attributable net profit (% change) Personnel costs / Sales Restated EBITA margin Restated EBITA margin Restated Net Personnel costs / Sales Net / Sales OpFCF / Sales OpFCF / Sales OpFCF / Sales Capital employed (excl. gdw /intangibles) / Sales ROE EBITDA / Financial charges		18 0 (1) (1) (1) (1) 15 (0) (0) 0 1 0 0 (1) 16 Dec. 17 69 30 99 33 1 11 11 54 Dec. 17 NC NS NC 2.9% NC 2.9% NC 0.0% 6.6.6% (0.1%) 161% 68.6% (0.1%) 161%	(5) 2 (1) 20 (26) (26) (7) (3) (9) 0 1 1 0 0 0 7 7 18 Dac. 18 79 30 110 36 1 1 15 20 20 20 11 10 11 11 11 11 11 11 11 11 11 11 11	0 (0) (3) (22 (14)) 8 (4) 3 0 (2) (2) 20 (2) 20 (2) 20 (2) 108 37 1 1 60 (2) 108 (3) 7 (1) 11 (1) 11 (1) 15	(1) 0 19 (13) (13) (15) (15) (2) 0 (5) 5 0 (0) (17) 14 1	1 (5) 21 (19) 2 (6) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3% 184.8% NC 0.6% 20.0% 20.0% 11.4% 1.0% 20.0% 186% 12.0x	0 (13) (13) (17) (26) (26) (28) (29) (29) (29) (29) (18) (19) (19) (19) (19) (19) (19) (19) (19	0 3 3 9 24 (25)5 (11) (2) (2) (3) 0 0 0 (1) 4 1 57 (2) 23 (2) 24 (2) 25 (2) 25 (2) 26 (2) 26 (2) 27	4 (1) (2) 40 (27) 13 (5) 9 0 0 (4) (5) 15 (6) 18 8 8 0 0 0 0 144 15 (6) 15 (7) 17.5 (6) 17.5	0 3 (4) 53 (28) 25 (10) 0 0 (5) (11) 47 46 33 156 94 63 32 34 40.5% 34.9% 20.6% 11.6% 22.5% 20.6% 11.6% 27.5% 20.6% 11.6% 27.5% 21.2% 35% 21.2%	3 (3) (57 (29) 28 (10) 18 (10) 0 (6) (11) 19 (10) 19 (3 (33) (33) (32) (32) (32) (11) (21) (0 0 0 (7) (15) (55 50 (27) (13) (13) (14) (15) (15) (16) (16) (16) (16) (16) (16) (16) (16
	EBITDA adjustment (b) Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANCESHEET HIGHLIGHTS (EURm) Net operating assets WCR BALANCESHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Restated attributable net profit (% change) Personnel costs / Sales Restated EBITA margin Restated EBITA margin Tax rate Net margin Capex / Sales OpFCF / Sales WCR / Sales Capital employed (excl. gdw /intangibles) / Sales ROE Gearing EBITDA / Financial charges Adjusted financial debt / EBITDA ROCE, excl. gdw /intangibles		18 0 (1) (1) (1) (1) 15 (0) (0) 0 1 1 0 0 (1) 16 Dec. 17 69 30 99 33 1 11 54 Dec. 17 NC NS NC 2.2.2% 13.0% 2.9% NC 0.0% 0.10% 0.3% 21.8% 68.6% (0.1%) 161% 9.1% 3.0% 3.1%	(5) 2 (1) 20 (26) (26) (7) (3) (9) (9) (0 7) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1	0 (0) (3) (22 (14) (8 (4) (15) (15) (15) (15) (15) (15) (15) (15	(1) 0 0 19 (13) 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	1 (5) 21 (19) 2 (6) (4) 2 (8) 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3% 184.8% NC 21.8% 14.9% 0.6% 11.4% 1.0% 2.2% 2.2% 2.5x 2.5x	0 (13) (13) (17) (26) (26) (29) (29) (29) (29) (29) (30) (48) (11) (20) (20) (48) (15) (20) (20) (20) (20) (20) (20) (20) (20	0 0 3 3 9 9 24 (25)5 (11) (2) (2) (3) 0 0 0 (11) 4 1 57 4 141 1 73 2 49 1 1 2 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 2 3 1 1 3 3 3 1 1 3 3 3 1 1 3 3 3 1 1 3 3 3 1 1 3	4 (1) (2) 40 (27) 13 (5) 9 0 0 (4) (4) (5) 9 59 148 8 80 0 29 148 15.6% 17.2% 17.6% 8.8% 6.2% 11.0% 18.9% 56% 18.6% 1.0x	0 3 (4) 53 (28) 25 (10) 0 0 (5) (11) 47 Doc. 25e 94 63 156 95 0 32 34 Doc. 25e 6.2% 40.5% 34.9% 20.6% 11.0% 27.5% 7.9% 21.2% 22.25 60.7% 21.2% 21.2% 21.2% 25.8% 25.8% 25.8% 25.8% 25.8% 25.8% 25.8% 25.8% 25.8% 25.8% 25.8% 26.7% 27.5% 2	3 (3) (57 (29) (29) (29) (29) (20) (10) (10) (10) (10) (10) (10) (10) (1	3 (33) (33) (33) (33) (33) (33) (32) (32
	EBITDA adjustment (b) Other items Other items Change in WCR Operating cash flow Capex Operating free cash flow (OpFCF) Net financial items + tax paid Free cash flow Net financial investments & acquisitions Other Capital increase (decrease) Dividends paid Increase (decrease) in net financial debt Cash flow, group share BALANGESHEET HIGHLIGHTS (EURm) Net operating assets WCR Restated capital employed, incl. gross goodwill Shareholders' funds, group share Minorities Provisions/ Other liabilities Net financial debt (cash) FINANCIAL RATIOS (%) Sales (% change) Organic sales grow th Restated EBITA (% change) Restated EBITA (% change) Restated EBITA (% change) Restated EBITA margin Restated EBITA margin Restated EBITA margin Capex / Sales WCR / Sales WCR / Sales WCR / Sales WCR / Sales ROE Gearing EBITDA / Financial charges Adjusted financial debt / EBITDA ROCE, excl. gdw /intangibles ROCCE, incl. gross goodwill		18 0 (1) (1) (1) (1) 15 (15) 0 (0) 0 0 1 1 0 0 (1) 16 Dec. 17 69 30 99 33 1 1 11 54 17 NC NS NC 22.2% 13.0% 2.9% NC 0.0% 10.7% 0.3% 21.8% 68.6% (0.1%) 161% 68.6% (0.1%) 161% 9.1x 3.0x	(5) 2 (11) 20 (26) (7) (3) (9) 0 1 1 0 0 7 18 Dec. 18 79 30 110 36 1 1 115 62 Dec. 18 12.6% NC 21.1% 2.4% 53.1% (8.6%) 16.8% (4.2%) (1.1%) 16.8% (7.9%) 18.8% 67.9% (7.9%) 18.8% 67.9% 2.5% 2.5%	0 (0) (3) (2) (2) (14) (8) (4) (3) (2) (2) (2) (2) (2) (2) (2) (2) (2) (2	(1) 0 9 (13) 7 (5) 2 0 0 (7) 7 (7) 14	1 (5) 21 (19) 2 (2) (6) (4) 2 (8) 0 0 9 14 Dec. 21 66 34 101 34 0 14 62 Dec. 21 26.3% NC 21.8% NC 21.8% NC 21.8% 14.9% 3.3% NC 20.6% 11.4% 58.6% 22% 186% 52.2% 186% 2.2% 186% 4.1%	0 (13) (13) (17) (26) (26) (29) (29) (29) (29) (29) (30) (18) (18) (19) (19) (19) (19) (19) (19) (19) (19	0 3 3 9 9 24 (255) (21 25) (22 25) (23 3) (25 25) (25	4 (1) (2) 40 (27) 713 (5) 9 0 0 0 (4) (5) 1 5 9 148 80 0 0 29 44 40 7.7% 115.6% 8.8% 27.5% 6.2% 11.0% 54.3% 61.0% 18.8% 18.6% 10.0% 10.5%	0 3 (4) 53 (28) 25 (10) 0 0 (5) (11) 47 Dec. 25e 63 156 95 0 32 34 Dec. 25e 6.2% 40.5% 34.9% 17.0% 20.6% 11.6% 27.5% 27.	3 (3) (57 (29) (29) (29) (28) (10) (18) (10) (10) (10) (10) (10) (10) (10) (10	3 (3) (3) (32 (11) (11) (15) (15) (15) (15) (15) (15)